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ABSTRACT 
 Several different investigations are discussed in this dissertation, with the 
common thread of using gold-containing nanomaterials in nuclear medicine 
applications.  Gold nanoparticles form a non-toxic surface layer that can be easily 
functionalized with biological targeting agents.  The first set of experiments focuses on 
attempts to develop cancer therapeutic and imaging agents using the radionuclides 
198/199Au.  Gold nanoparticles with both passive (gum arabic coated) and active 
(bombesin) targeting are examined.  Additionally, the possibility of attaching a chelate 
to bind the PET imaging radionuclide 64Cu with DTDTPA is explored.   
 The second area of emphasis focuses on developing a nanoparticle capable of 
retaining the radioactive decay daughters of the in vivo α generator 225Ac.  This 
generator system produces 4 successive α emissions in its decay chain.  However, 
daughter products escape and cause renal toxicity.  A LnPO4 nanoparticle coated with 
gold can both retain the energetic daughter products in the decay chain and be easily 
functionalized to deliver radiation to biologically relevant targets in vivo.   
 Nanoparticle technology allows for the combination of multiple therapeutic and 
imaging modalities by a single platform.  Unlike conventional approaches, the multi-
atom nature of nanoparticles allows for delivery of large, varied payloads to biological 
receptors.  The nanomaterials discussed here can theoretically be used for any 
combination of PET/SPECT imaging, MRI contrast, or α/β-  radiotherapy. 
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CHAPTER 1: 
INTRODUCTION TO NANOPARTICLE BASED RADIATION THERAPY 
 
 
1.1 Cancer Epidemiology 
 Great strides have been made in the diagnosis and treatment of a wide variety of 
cancers.  Relative survival rates of all cases have risen to 67% for cancers diagnosed 
between 2001 and 2007, compared with only 45% for cancers diagnosed between 1975 
and 1977.  Despite this progress, cancer remains the second leading cause of death in 
the United States, accounting for nearly one in every four deaths.1 Globally, cancer 
incidence is expected to rise 75% by 2030.2  Early diagnosis and detection of cancer 
increases the success of therapeutic regimens.  Unfortunately, many types of cancer will 
metastasize, creating tumors in distant parts of the body prior to diagnosis.  Neoplastic 
cells can lie dormant for decades before developing into tumors. 3  The presence of 
metastatic disease drastically decreases survival.  For example, primary breast cancer 
tumors are currently cured with a 98.6% success rate, as measured by the relative 5 year 
survival fraction.  Regional spread of tumor cells via the lymphatic system lowers 
survival expectancy to 83.8%.  In contrast, only 23.3% of breast cancer patients with 
distant, metastatic spread of cancer survive five years after diagnosis.4   
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1.2 Current Oncology Therapies 
 Current cancer treatment falls into three basic categories: surgery, 
chemotherapy, and radiotherapy.  Most patients diagnosed with cancer undergo some 
sort of surgery to remove large, primary tumors.  When the tumor is localized, surgical 
resection effectively treats a wide variety of tumors.  Unfortunately, a number of factors 
can render a tumor inoperable.  The tumor may be connected to or embedded within a 
vital organ such as the heart or brain or the tumor may have metastasized to distant 
sites, rendering removal of the original tumor ineffectual.  Finally, the tumor may not 
have adequate margins of neighboring healthy tissue to be safely removed.  Even a 
small remaining neoplastic fraction will quickly regenerate the removed tumor mass.  
Surgery represents an effective, if invasive, treatment for isolated solid primary tumors. 
 Inoperable tumors, metastases, and dormant circulating tumors require other 
methods of treatment.  Chemotherapy, the use of cytotoxic chemicals to attack 
neoplastic cells, can be effective as a standalone therapy or in combination with surgery 
and/or radiation to prevent the spread and recurrence of surgically removed 
neoplasms.5  Most chemotherapeutic agents act non-specifically on rapidly dividing cells 
which include tumor cells, bone marrow, intestinal cells, and hair follicles.  The effect of 
chemotherapeutics on healthy tissues causes numerous side effects associated with 
cancer treatment, including decreased immune function and anemia from bone marrow 
destruction, nausea and vomiting from intestinal cell toxicity, and alopecia (hair loss) 
from the loss of hair follicles.6,7,8   
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 Radiation therapy is a method often used either as a standalone treatment or in 
combination with surgery and/or chemotherapy.  The two predominant types of 
radiotherapy currently in clinical use are external beam radiotherapy and 
brachytherapy.  External beam radiotherapy uses either x-rays, protons, or α particles to 
destroy the target cancer cells, often guided by advanced imaging techniques such as 
magnetic resonance imaging (MRI) and computed tomagraphy (CT).9  However, external 
beam radiotherapy disrupts healthy tissue as it traverses the path to the tumor, causing 
harmful side effects.  Brachytherapy uses implantable “seeds” containing a radioactive 
isotope.  These seeds are placed in the immediate vicinity of the tumor and deliver a 
continual dose until the source is removed or decays.  Implantable brachytherapy seeds 
are particularly common and effective in treatment of inoperable prostate cancer.10  
Brachytherapy seeds also have the potential to shift in vivo, delivering dose to healthy 
tissue or causing a radiological hazard if excreted from the body.  Large doses to normal 
tissue result in undesirable side effects such as incontinence and impotence.11 
1.3 Targeted Radiotherapies and Types of Therapeutic Radiation 
 In order to simultaneously improve cancer patient outcomes and quality of life, 
more specific therapeutic modalities must be pursued.  Side effects would be drastically 
reduced, if not eliminated, by development of radiotherapeutic compounds that spare 
healthy tissue while delivering cytotoxic doses to tumor cells.  Currently, there are two 
targeted radiotherapy compounds approved by the FDA for human use.  BEXXAR utilizes 
the β- particle emitted from 131I in treatment of follicular lymphoma while Zevalin 
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incorporates the β- emitting radionuclide 90Y for treatment of non-Hodgkin’s 
lymphoma.12,13 
There are two distinct types of radiation used for therapeutic purposes.  
Photons, β- particles, and Auger electrons deliver low linear energy transfer (LET) 
radiation while protons and α particles deliver high LET radiation.  Low LET and high LET 
radiation differ drastically in their properties and mechanism of action and therefore 
their clinical applicability.  Both types of radiation destroy cancer cells by inducing 
double strand breaks in cellular deoxyribonucleic acid (DNA).  This type of lesion proves 
difficult for the cell to repair and leads to fatal chromosomal aberrations.14  Low LET 
radiation acts primarily by generating reactive oxygen species as a result of ionization 
events.  Because low LET radiation acts, at least in part, via these intermediaries, their 
efficacy can be decreased based on external factors such as cell oxygenation or cell cycle 
considerations.15,16  Cells which are hypoxic or anoxic require 2-3 times more activity of 
low LET radiation to produce the same level of toxicity.17  Dividing cells are able to repair 
DNA damage, including double strand breaks, during the S phase of mitosis when 
chromosomes are being duplicated.  They are least likely to successfully repair DNA 
lesions during the mitotic, or M phase.15 
In contrast, high LET radiation creates double strand breaks by acting directly on 
DNA.  As a result, the effects of high LET radiation depend less on external factors.  The 
path length between ionization events closely approximates the distance between 
cross-sectional base pairs in the DNA molecule.15  Only a few traversals of the nucleus is 
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required to generate a cell kill as opposed to the thousands necessary in β- therapy.18  
Thus, α and proton therapy can cause tumor cytotoxicity with only a fraction of the 
activity required in β- therapy, i.e. α therapy has a much higher relative biological 
effectiveness.  Because high LET radiation deposits its energy in a small, localized space, 
it limits collateral damage to healthy tissue.  Unfortunately, this effect also limits the 
scope of α therapy to small micrometastases, disseminated/blood-borne neoplasms, 
and film-like peritoneal tumors.19  Crossfire effects from the longer range of β- particles 
provide a better option for treating large, solid tumors which cannot be surgically 
resected or treated with chemotherapy/external beam radiotherapy.20 
The bifunctional chelate approach represents a major paradigm for 
radiopharmaceutical research in both α and β- therapy.21  In this approach, a radiometal 
is stably sequestered by a chelating agent bound to a targeting molecule such as a 
peptide or antibody.  The chelate must be able to bind the radiometal quickly relative to 
the radionuclide half-life in order to maximize radiochemical yield.  It also must form a 
very stable bond (both thermodynamically and kinetically) that will remain impervious 
to attack by the various proteins and salt concentrations found in the biological 
environment.    
1.4 Nanoparticles for Cancer Therapy 
Recently, nanoparticles have emerged as an exciting alternative to molecular 
chelating agents for delivering radioisotopes in cancer therapy.  The wide swath of 
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constructs that falls under the umbrella of nanoparticles possess a number of exciting 
properties for delivery of both radioactive and non-radioactive therapeutic agents.  
Nanoparticles possess extraordinary versatility, where the same platform can be 
radically changed by modifying size, shape, and surface characteristics of the particle.  
These changes alter the pharmacokinetic profile of the nanoparticle.  In vivo 
characteristics such as biodistribution, excretion pathway, and drug release timing can 
all be tuned by slight changes in particle composition.22   
Many important processes in the body are regulated by receptors which are 
present in very low concentrations, yet have a very high affinity for their associated 
substrate.  These low receptor concentrations make them difficult to target for 
therapeutic and imaging purposes.23  Using a nanoparticle rather than a molecular 
bifunctional chelate can drastically increase the dose delivered to each receptor site.  
While a traditional molecular chelate typically binds one radiometal, a single 
nanoparticle can deliver multiple radioactive atoms to a single receptor site.  
Additionally, the size of the nanoparticle makes it possible to link multiple targeting 
vectors onto a single particle.  Emerging data on tumor heterogeneity suggests that 
variations between tumor cells even within a single tumor type may frustrate attempts 
to effectively target all of the tumor cells.  Incorporating multiple targeting mechanisms 
onto each particle holds the potential to broaden the effect of targeted 
radiopharmaceuticals.24   
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Nanoparticles possess some degree of innate targeting towards tumors in vivo.  
The remarkable growth rate of tumors requires recruitment of neovasculature to 
provide sufficient nutrients to the neoplasm.  Tumor cells often release large amounts of 
vascular epithelial growth factor to promote angiogenesis and vascular permeability.  As 
a result of the increased permeability, large constructs such as nanoparticles and 
liposomes are filtered from the bloodstream into the interstitial space surrounding the 
tumor.  In normal tissue, these species are typically removed from the interstitial space 
by the lymphatic system.  However, in tumor tissue the lymphatic system is largely 
disabled, increasing the residence time of the nanoparticle in the interstitial space.  This 
combination of leaky, permeable vasculature and disabled lymphatic function is known 
as the enhanced permeability and retention (EPR) effect.25   
The increased size of nanoparticle constructs relative to bifunctional chelate 
platforms presents unique challenges.  While increased passive tumor targeting occurs 
via the EPR effect, specific targeting is hindered.  Large nanoparticles have difficulty 
extravasating out of the vascular space, potentially limiting application to tumors with 
vascular targets, blood-borne neoplasms, and peritoneal cancers.  Various techniques 
such as mild hyperthermia can improve nanoparticle extravasation on clinically relevant 
time scales.26 
Much of the work on nanotechnology has focused on gold nanostructures.  
While gold colloids were known and used in medieval times as a stain, monodisperse 
gold nanoparticles were first routinely synthesized in the modern era by Turkevich, et al. 
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in 1951.27  Their procedure produces spherical gold nanoparticles of diameters from 10-
20 nm in aqueous solution.  Ionic gold (Au+3) is reduced by citrate with heat to neutral 
gold.  Brust later pioneered an organic phase gold synthesis and solvent transfer method 
by modifying the surface groups on the nanoparticle.  This method involves reduction of 
ionic gold by sodium borohydride in toluene with tetraocytlammonium bromide capping 
agent.28  Due to its relative inertness and facile functionalization, gold makes an 
attractive surface coating for other nanoparticle materials.  For instance, the surface 
plasmon resonance of gold provides a visual marker for MRI active, gold coated Fe3O4 
particles.29   
1.5 In vivo α generator therapy  
 Alpha generator therapies use radionuclides with four (223Ra, 225Ac) or five (227Th) 
α particles in their decay chain.  Decay chains for 227Th and 225Ac are shown in Figures 
1a30 and 1b.  Currently there are two barriers to development of clinically relevant in 
vivo α generators.  The first challenge consists of producing a reliable and sufficient 
supply of the radionuclides.  Secondly, a means of sequestering the radioactive daughter 
products in vivo must be devised to prevent toxicity to non-target tissue. 
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Figure 1.5.1 A and B: Simplified decay schemes for 227Th and its parent radionuclide, 
227Ac (A) and for 225Ac (B). 
B 
A 
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 Currently, 225Ac is available from a 229Th generator produced at Oak Ridge 
National Laboratory.31  The 229Th comes from legacy stockpiles of 233U developed during 
the cold war era and produces no carrier added 225Ac.  Alternative strategies for 
production of 225Ac include using stockpiled 226Ra seeds in a 226Ra(p, 2n)225Ac reaction.  
This reaction has been used with proton energies of 16.8 MeV on a 0.0125 mg target for 
7 hours with a current of 10 μA to produce 78 kBq of 225Ac.32  This method also produces 
224Ac, which is decayed away before separation and 226Ac, which has a negligible yield at 
16.8 MeV.  A third method for production of 225Ac involves the spallation reaction on 
232Th.  Cross section data obtained at 800 MeV proton energy indicate that 10 day 
irradiations at the Los Alamos Neutron Science Center facility will be capable of 
producing 740 GBq of 225Ac.  A non-negligible amount of 227Ac (0.25%) will also be 
produced.  An additional 13 GBq of no carrier added 225Ac could be made available from 
simultaneous production of the 225Ra parent.33  Further studies are required to 
determine if the 227Ac impurity is sufficient to cause long term radiation damage in vivo. 
 
Figure 1.5.2: Purified sample of 1.85 GBq of 225AcCl3.  Alpha particles from the sample 
cause the glass vial to radioluminesce. 
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 Thorium-227 and 223Ra are primarily available in small quantities as decay 
products of 235U and 227Ac.  Both the United States and Europe possess modest 
stockpiles of 227Ac.  The 227Ac parent can also be produced with good yield from the 
226Ra(n,γ)227Ac reaction.34  Successive neutron capture on 227Th can produce 228Th and 
229Th, the parent isotope for 225Ac.35 
 Beyond radionuclide availability, the emission of multiple α particles presents 
unique challenges for specific delivery of therapeutic radiation.  Namely, the chemical 
behavior of daughter radionuclides often differs radically from that of the parent 
radionuclide.  For example, the bivalent 223Ra decays to the unreactive noble gas radon 
while the trivalent 225Ac decays to the monovalent francium.  Chemical behavior along 
the decay chain of in vivo generators switches from cationic to anionic and back again, 
frustrating attempts to contain the radionuclides within a single chelate.  The recoil 
energy of the daughter radionuclides presents an equally daunting challenge.  Each α-
particle emission creates a recoil energy of >100 keV (four orders of magnitude greater 
than the energy of a typical covalent bond) on the daughter radionuclide.  As a result, 
daughters chelated by traditional molecular species will not remain bound to the 
bioconjugate at the targeting site.36   
The in vivo α generator 223Ra provides an example of an effective targeted α 
therapy generator for treatment of metastatic bone cancer.37 Radium-223 chloride 
(Alpharadin) has been granted Fast Track designation by the U.S. Food and Drug 
Administration for the treatment of hormone-refractory prostate cancer in patients with 
12 
 
bone metastases.38  It is effective because radium mimics calcium in vivo, providing a 
high affinity for bone.  Further, the daughter products either have short  half-lives (< 5 
minutes) or have a high affinity for bone  (211Pb, t1/2 = 36 m).  Translation of in vivo α 
generators to anything besides metastatic bone cancer with a calcium mimic will require 
a different mechanism for both delivering and retaining the radioactive daughters in the 
target tissue. 
  Other methods under investigation for sequestration of α emitting daughters 
involve chelation with DOTA or analogous macrocyclic chelators and incorporation into 
liposomes/polymerosomes, fullerenes, or nanocrystals.  In the case of 225Ac based 
therapeutics, 213Bi daughter migration to the kidney represents the dose limiting factor.  
Scavengers such as 2,3-dimercapto-1-propanesulfonic acid (DMPS) and 
dimercaptosuccinic acid (DMSA) or non-radioactive Bi competition mitigate, but do not 
effectively eliminate this limitation.39   
Another challenge is that labeling efficiency for molecular chelates depends on 
the ratio of chelate to 225Ac.  Examples from literature studies typically exhibit either 
high synthetic yield or high specific activity, but not both.  In order to achieve high 
synthetic yield (>97%), Essler et al. use huge excesses of chelate/peptide conjugates 
(6,700 conjugates per 225Ac atom).  The resulting low specific activity (72 MBq/μmol) 
would be suitable only for receptors that are in high abundance in vivo.40  Effectively 
targeting receptors with low in vivo concentrations requires high specific activity.  Song 
et al. produce higher specific activity bioconjugates (4.44 GBq/μmol) but at the expense 
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of labeling efficiency (12.0%).41  Given the limited supply of 225Ac and the importance of 
receptors with low concentrations, development of a high yield, high specific activity 
synthesis is paramount. 
Single and multi-layer liposomes are under evaluation for their ability to 
sequester 225Ac and its α-emitting daughters.  Unfortunately, preparations of single wall 
liposomes suffer from both low 225Ac incorporation (6.4%) and poor daughter retention 
(213Bi <10%).42  Further, single wall liposomes struggle to quantitatively retain the 225Ac 
parent radionuclide.  Despite the lofty sequestration predictions of theoretical models, 
experimental retention of 225Ac and 213Bi appears much lower.  Active loading of 
liposomes increases 225Ac incorporation to 73%, though 225Ac retention only reaches 
81%.43  Despite the higher synthetic yield, 213Bi retention does not improve.  Recent 
theoretical work postulates 213Bi retention as high as 80% in multi-walled 
polymerosomes.  The proposed polymerosomes require a large bulk (800 nm in 
diameter) to achieve this level of retention.44  Such large particles would not extravasate 
out of the vasculature and would not capitalize on the enhanced permeability and 
retention effect.45,46  A final strategy for 225Ac sequestration involves incorporation into 
fullerenes.  This method exhibits a low synthetic yield (1%) and little to no 221Fr daughter 
sequestration.47 
 A final method for retaining 225Ac and its α-emitting daughter radionuclides 
directly incorporates Ac into the crystal structure of a nanoparticle.48,49  Due to 
isomorphism between Ac and the lanthanides, Ac co-crystallizes with lanthanide 
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phosphates.  Both Ac and the lanthanides (with the exception of cerium) almost 
exclusively form +3 cations.  Additionally, the light lanthanides are large enough to 
approximate the ionic radius of Ac.  Incorporating Gd into the crystal provides a 
sufficient paramagnetic moment for separation of the nanoparticles with a NdFeB 
magnet.49  Addition of a Au surface layer facilitates surface modification, prevents Gd 
leakage in vitro, and prevents in vivo reactivity.  Ranges of recoiling 225Ac daughters in 
gold calculated by the stopping range of ions in matter/transport of ions in matter 
(SRIM/TRIM) program are shown below in Table 1.5.1.50 
Table 1.5.1: Range and kinetic energies of 225Ac daughter products 
Daughter Decay energy (MeV) Daughter energy (keV) Range in gold (nm) 
221Fr 6.3 112  11.3 
217At 7.1 129 12.5 
213Bi 5.9 109 11.3 
209Pb 8.4 158 12.0 
 
 In addition to Alpharadin, there are two other current clinical trials of in vivo α 
generators involving 225Ac.  The first phase I study is currently recruiting patients at 
Memorial Sloan Kettering Cancer Center in New York.  This clinical trial utilizes the 
humanized antibody HuM195 against the CD33 protein, found in acute myeloid 
leukemia.  In the study, 225Ac is chelated to DOTA, which is then bound to HuM195.51  
The second study, organized by M.D. Anderson Cancer Center, uses the antibody 
lintuzumab for treatment of acute myeloid leukemia.52 
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CHAPTER 2: 
GOLD NANOPARTICLES FOR THERAPY OF UNRESECTABLE 
PROSTATE CANCER 
 
 
2.1. Introduction 
2.1.1. Production, Separation, and Nuclear Properties of Radiogold  
 Prostate cancer is the most common form of cancer in males, with 241,000 new 
cases estimated to be diagnosed in 2012.1  Many of these tumors are not eligible for 
surgical resection.  Methods such as radiotherapy/brachytherapy successfully treat 
these neoplasms or shrink them to the point where they can be surgically resected.   
 Radiogold possesses favorable properties for β- therapy of tumors.  Production 
of radiogold occurs via neutron irradiation.  Only one stable isotope of gold, 197Au, 
occurs in nature, making enrichment unnecessary.  Neutron absorption by natural gold 
produces a large amount of 198Au and a smaller fraction of 199Au.  A summary of their 
nuclear properties is shown below in Table 2.1.1.  
 Both gold radionuclides have approximately a 3 day half-life and release a β- 
particle.  Lower ratios of 198Au/199Au (higher production of 199Au) are produced using a   
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Table 2.1.1:  Properties of 198/199Au53,54 
Radionuclide Half-Life (d) β- energy (keV) γ energy (keV) σthermal (b) σepithermal (b) 
197Au Stable   1550 98.7 
198Au 2.70 719 412 (96%) 26,000  
199Au 3.14 453 158 (40%)   
 
high thermal/epithermal flux and long irradiation times.  The high energy γ ray at 411.8 
keV, which occurs with 96% abundance in 198Au, presents a major drawback for 
radiotherapy purposes.54  This γ ray delivers a whole body radiation dose to healthy 
tissue in the patient.  In contrast, 199Au has an ideal imaging γ ray of 158 keV (40% 
abundance).54  Current single photon emission computed tomography (SPECT) 
equipment designed to image the 140 keV γ ray from 99mTc will easily detect the 199Au γ 
with little or no modification.  Monte Carlo N-Particle analysis of these two γ rays in a 
standard reference man indicates that the 198Au γ gives a whole body dose 2.37 times 
higher than the 199Au γ.55  The non-specific, whole body dose can disrupt normal 
function and lead to carcinogenesis in other parts of the body. 
No carrier added 199Au, which will provide a lower whole body γ dose, can be 
produced by neutron irradiation of 198Pt (7.16% natural abundance).53  The 
198Pt(n,γ)199Pt reaction has a high cross section (3.8 barn thermal, 56 barn epithermal) 
and the 199Pt decays into 199Au with a half-life of 30.8 minutes.53  Solvent extraction with 
ethyl acetate or cation exchange can be used to separate Au(III) ions from their Pt(IV) 
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counterparts in the dissolved target.  After irradiation, the Pt target is dissolved in a 
glove box using 500 μL of boiling aqua regia in a glass liquid scintillation vial.  The 
resulting solid is redissolved in 500 μL of 1 M HCl and again evaporated to dryness.  The 
solid is prepared for extraction by addition of 500 μL of 3 M HCl and transfer to a plastic 
V-bottom vial.  Extraction occurs through addition of an aliquot of ethyl acetate (300 
μL), vortexing, and pipetting of the ethyl acetate layer.  This process is repeated until 
adequate yield is achieved.  After extraction, the ethyl acetate is evaporated and the 
remaining impurities are digested with 300 μL of 35% H2O2.  The gold is then 
redispersed in 0.05 HCl for use.  The separation process has high yield (>90%) and 
radiochemical purity (>99%).56,57 
2.1.2 Chemical Reactivity of Gold 
Chemically, gold exhibits three easily accessible oxidation states.  Most 
commonly, gold exists as solid, neutral gold.  Au0 has historically been used in the 
production of coins, hence its designation as one of the unreactive coinage metals.  
Under harsh conditions, such as immersion in hot aqua regia, gold will oxidize to the 
Au+3 state in the form AuCl4
-.  Reduction of AuCl4
- to form nanoparticles is favorable, 
with a standard reduction potential of 1.002 V from AuCl4
- to Au0.  Partial reduction of 
AuCl4
- to AuCl2
- (0.93 V) produces Au+1 which can then be further reduced to Au0 (1.154 
V).58 
While all three gold oxidation states are currently being investigated for 
potential therapeutic application, ionic gold shows instability in biologically relevant 
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media.  Reduction to colloidal gold is seen in many Au+3 and Au+1 compounds due to the 
body’s natural redox potential.59,60  Stabilizing Au+3 in vivo presents an even more 
daunting challenge in light of proteins evolved to chelate trivalent metal ions such as 
Fe3+.  For this reason, many groups are using neutral gold in nanoparticulate form for 
therapy.  Au0 remains inert in vivo and, given the proper surfactant, can be highly water 
soluble.  Gold nanoparticles are among the most studied and consequently best 
understood nanomaterials.  
2.1.3 Production, Nuclear, and Chemical Properties of 64Cu 
 While 199Au provides SPECT capability, many applications call for the higher 
spatial resolution inherent from positron emission tomography (PET) imaging.  This 
imaging requires a positron emitter such as 64Cu.  Copper-64 decays by β- (38.4%), β+  
(17.8%), and electron capture (43.8%) decay.  Copper-64 can be produced from the 
64Ni(p,n)64Cu reaction on an enriched 64Ni target at modest cyclotron energies (12 MeV).  
The reaction and separation via ion exchange chromatography produce 64Cu with high 
radionuclidic purity (>99%).61  The decay scheme of 64Cu is shown in Figure 2.1.2. 
 
Figure 2.1.1: Simplified decay scheme of 64Cu. 
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 Ionic copper is more stable than ionic gold, and can be chelated with a number 
of different ligands.  When chelated, copper exists predominantly in the +2 oxidation 
state.  Nitrogen based, macrocyclic chelating agents such as 1,4,8,11-
tetraazacyclotetradecane-1,4,8,11-tetraacetic acid (TETA) effectively bind Cu2+ in vitro, 
but show instability in vivo.  The crossbridged analog to TETA, CB-TE2A, adds copper 
slowly but exhibits high stability in vivo.62  Substituting phosphonic acid arms for the 
acetic acid arms of the TE2A system increases the kinetic speed of Cu2+ incorporation 
while retaining high in vivo stability.62    Other radionuclides of copper also may prove 
useful for radiotherapy and imaging, with 67Cu functioning as a β- therapeutic and 60Cu 
having potential as a PET radionuclide. 
2.1.4 Specific Aims 
 The first portion of this work assessed the ability of non-specifically targeted 
nanoparticles to serve as brachytherapy agents.  In these experiments, the gold 
nanoparticle surface is passivated by the biocompatible surfactant gum arabic.  
Nanoparticles are injected intratumorally (I.T.) and monitored for retention in tumor 
tissue over a 1 month period.  Rather than painfully inserting hundreds of macroscopic 
seeds into the prostate, a single injection of nanoparticles delivers a prodigious number 
of microscopic seeds directly to the tumor.   
The second portion of this work evaluates a specifically targeted β- therapeutic 
consisting of 198/199Au nanoparticles coated with starch and directed in vivo by a 
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truncated bombesin targeting agent.  Targeting efficacy is monitored by multiple 
injection pathways in comparison to untargeted nanoparticles and bombesin-targeted 
bifunctional chelate constructs.  Bombesin targets the gastrin-releasing peptide (GRP) 
receptors in cells.  These GRP receptors are over expressed in prostate cancer cells, with 
as many as 44,000 receptors per PC-3 prostate cancer cell.63  While the full length 
bombesin peptide consists of 14 amino acids, truncated peptides based on amino acids 
7-14 show improved targeting and pharmacokinetics as a result of amino acid 
substitution or modified chelation/spacer groups.64  The full length bombesin peptide 
(Pyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2) is shown in Figure 2.1.1.   
 
Figure 2.1.2: Structure of the 14 amino acid bombesin peptide. 
 The third portion of this work focuses on development of a 64Cu containing gold 
nanoparticle.  Radiometal chelation with non-macrocyclic compounds such as 
diethylene triamine pentacetic acid (DTPA) can prove unstable in vivo.65  Binding 
multiple DTPA chelates to a single nanoparticle could provide a sandwich style structure 
which would sufficiently stabilize the 64Cu.  This development would generate a PET 
imaging agent with the passive targeting advantages of a nanoparticle. 
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2.2 Gum Arabic Gold Nanoparticle Experimental 
2.2.1 Materials  
 All chemicals were obtained from Sigma-Aldrich and were at least American 
Chemical Society (ACS) grade.  Materials were used as received without further 
purification or modification.  All animal experiments were conducted according to the 
procedures set forth by the Institutional Animal Care and Use Committee of the 
University of Missouri-Columbia.   
2.2.2 Gum Arabic Gold Nanoparticle Synthesis 
 Gum arabic (2.94 mg) was dissolved in 6 mL of 18 MΩ water.  NaAuCl4 (100 µL, 
0.1 M) was added to the gum arabic solution in a 20 mL glass scintillation vial.  Tris-
hydroxylmethyl phosphine alanine (THPAL, 3.9 mg) was dissolved in 116 μL of water.  
The dissolved gum arabic solution was heated under reflux, then 60 µL of THPAL 
solution was added.  A deep purple color forms immediately upon addition of the 
THPAL.  The nanoparticle solution was heated for one minute, then cooled with stirring 
for 30 minutes.  The solution was neutralized to physiological pH by addition 1 M NaOH 
and HCl.  Dulbecco’s phosphate buffered saline (DPBS) was added to buffer the sample 
and restore the volume to 6 mL.  The nanoparticle solution was diluted by taking 100 µL 
of solution and mixing with 900 µL of water for Ultraviolet-visible (UV-Vis) 
measurements on an Ocean Optics USB 2000 spectrometer.   
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2.2.3 Biodistribution and Animal Studies 
 Biodistribution studies were performed by Lisa Watkinson and Terry Carmack 
under the supervision of Prof. John Lever and Dr. Jeff Smith at the Harry S Truman 
Memorial Veterans Affairs Hospital.  The non-radioactive gum arabic coated 
nanoparticles (30 μL) were injected I.T. into randomly selected female imprinting 
control region severe combined immunodeficient (ICRSCID) mice (n=7) with average 
body mass of 23.01 ± 1.76 g.  Human PC-3 prostate cancer xenografts were grown in the 
mice prior to injection with average tumor volume of 0.052 ± 0.029 g.  PC-3 cells were 
obtained from American Type Culture Collection and were maintained by the University 
of Missouri Cell and Immunobiology Core Facility.  Control mice (n=7) were injected with 
30 μL of DPBS solution I.T.  Over the next month, tumors were measured using external 
calipers to estimate tumor volume.  Additionally, animal weight was monitored as an 
indicator of overall health.  If an animal experienced drastic weight loss, it was 
euthanized and its organs harvested.  After 30 days, the surviving mice were sacrificed 
and their organs harvested (bladder, kidney, small intestine, large intestine, liver, lung, 
pancreas, spleen, muscle, and tumor) for analysis by neutron activation analysis (NAA).  
Each organ was freeze dried and loaded into a 2/5 dram (1.48 mL) polyethylene vial 
before co-irradiation with gold standards.  Samples were allowed to decay for three 
hours before counting. 
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2.3 Gum Arabic Gold Nanoparticle Results and Discussion 
 Gum arabic coated gold nanoparticles exhibited a plasmon resonance absorption 
maximum at 539 nm.  This absorption corresponds with the absorption of gum arabic 
nanoparticles previously measured by scanning transmission electron microscopy (TEM) 
of ~15 nm in diameter.  Previous dynamic light scattering (DLS) measurements indicate 
that these 15 nm nanoparticles have a hydrodynamic diameter of 85 nm and a zeta 
potential of -24.5 mV.57   
 During the experiments, two mice from the nanoparticle treatment group and 
two mice from the DPBS control group showed significant weight loss and were 
euthanized before the end of the thirty day trial period.  Within the surviving mouse 
population, nanoparticles injected into the tumor showed long residence times, with 
80.0 ± 18.7% of the injected dose (ID) retained over the 1 month time period.  
Nanoparticles which did not remain in the tumor were excreted primarily via the 
reticuloendothelial system (RES).  Next to the tumor, the highest organ uptake following 
IT injection occurred in the liver, with 1.4 ± 0.4 %ID present.  Uptake in the spleen (0.11 
± 0.01 %ID) is also indicative of the RES clearance pathway.  The total amount of gold 
detected in the collected organs accounted for 83.9% of the initial ID.  Undetected gold 
nanoparticles were presumably present in small amounts in the remainder of the animal 
or excreted over the one month study period.  The average minimum detectable 
amount of gold in tissue via the NAA measurements was approximately 10 ng. The 
biodistribution of the particles is shown in Figure 2.3.1. 
24 
 
 
Figure 2.3.1: Gum arabic coated gold nanoparticles present in SCID mice one month 
following I.T. injection in PC-3 xenografts measured by NAA. 
 Non-radioactive gum arabic coated gold nanoparticles are retained in the tumor 
to a much higher degree than radioactive nanoparticles.  Previous therapy studies done 
by Chanda, et al. utilizing 198Au gum arabic nanoparticles indicate that only 19.9 ± 4.2% 
of the ID was retained in the tumor after one month.66  In the radioactive study, most of 
the tumor tissue was necrotic at this point, which was not observed with the non-
radioactive nanoparticles.  The difference may possibly be explained through differences 
in clearance between the necrotic tissue found in mice treated with radioactive 
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nanoparticles and the viable tumor tissue found in mice treated with non-radioactive 
nanoparticles. 
 Tumor sizes between groups receiving DPBS and non-radioactive gold 
nanoparticles showed no statistically significant difference in tumor volumes or mass (p-
value = 0.1258).  In the group receiving gold nanoparticles, tumor volume averaged 0.65 
± 0.21 cm3 while in the group receiving PBS, tumor volume averaged 0.49 ± 0.43cm3.  
After sacrifice, tumors from the treatment group had an average mass of 0.888 ±  0.193 
g while tumors from the PBS group had an average mass of 0.704 ± 0.225 g.  These 
results are shown in Figures 2.3.2 A and B. 
 Gum arabic coated 198Au nanoparticles have shown tremendous potential to 
shrink tumors in unresectable prostate cancer.67  However, it had not been rigorously 
established that this tumorcidal effect was due to the radioactivity present rather than 
to some innate cytotoxicity of the gold nanoparticles.  While some gold nanoparticles 
show cytotoxicity, this most often occurs in cationic particles of <2 nm diameter.68  In 
this case, cytotoxicity results from the small positively charged nanoparticle disrupting 
the negatively charged cellular membrane.69  Membrane disruption inhibits the cell’s 
ability to maintain homeostasis and regulate its environment, ultimately leading to cell 
death. 
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Figure 2.3.2 A and B:  Tumor volume (A) and Tumor mass (B) after treatment with gum 
arabic gold nanoparticles.  No significant difference was observed between mice treated 
with DPBS and mice treated with non-radioactive gum arabic coated gold nanoparticles. 
 The gum arabic nanoparticles used in the experiment show no statistically 
significant cytotoxic effect on the tumor.  Additionally, the nanoparticle group showed 
A 
B 
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no additional weight loss or other symptom relative to the DPBS group.  Two mice from 
each group were sacrificed early as a result of deteriorating health and tumor associated 
weight loss.  Therefore, radioactivity from 198Au is responsible for the tumor shrinking 
properties seen in I.T. injections, rather than any chemical properties of the 
nanoparticles. 
2.4 Starch-Bombesin Gold Nanoparticle Experimental 
2.4.1 Materials and Radiogold Production 
 All chemicals were obtained from Sigma-Aldrich and were at least ACS grade 
unless otherwise noted.  Materials were used as received without further purification or 
modification.  Water (18 MΩ) was produced from an in-house system. Bombesin 7-14 
(hereafter referred to as simply bombesin) was purchased from Anaspec.  Radiogold 
was produced by irradiating a 0.75 mg gold foil at the University of Missouri Research 
Reactor (MURR) for 6 hours in a thermal neutron flux of 8*1013 n/cm2/s.  After 
irradiation, the quartz vial containing the gold target was washed of contaminant 
radioactivity and opened in a glove box where it was dissolved in 800 μL of aqua regia.  
The aqua regia was evaporated and the gold dissolved in 400 μL of 1.0 M HCl.  This HCl 
was evaporated and the gold reconstituted in 800 μL of 0.05 M HCl.   
2.4.2 64Cu-Bombesin Conjugate Synthesis 
[64Cu- 1,4,7-Triazacyclononane-1,4-diacetic acid (NO2A)-bombesin] conjugates 
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were synthesized by Prof. Jeff Smith’s group at the Harry S Truman Veterans Affairs 
Hospital.70  The synthesis was conducted by adding 64CuCl2 (260 MBq, 2.83×10
−11 mol, 
MDS Nordion) to a plastic tube containing bombesin-NO2A conjugate (20 μg) and 250 
µL of 0.4 M ammonium acetate. The pH of the reaction mixture was adjusted to ∼7 by 
the addition of 2 mM NaOH then incubated (80°C, 1 h). Fifty microliters of 10 mM DTPA 
solution was added to scavenge unbound radioactivity.  The radiolabeled conjugates 
were then purified by reverse phase high performance liquid chromatography and 
collected into 100 µL of 1 mg/ml bovine serum albumin (BSA) stabilizing agent with 25 
μg ascorbic acid.  Figure 2.4.1 shows the synthetic conjugate.70  
 
Figure 2.4.1: Molecular structure of 64Cu-NO2A-Bombesin conjugate  
2.4.3 Starch Gold Nanoparticle Synthesis 
 Starch (12.5 mg) was dissolved in 6 mL of 18 MΩ water.  NaAuCl4 carrier (95 µL of 
0.1 M solution in water) and H198AuCl4 (190 MBq in 225 µL of 0.05 M HCl) were added to 
a 20 mL glass scintillation vial.  The solution was neutralized by adding 10 µL of 1 M 
NaOH, then heated under boiling conditions.  THPAL solution (30 μL, 0.1 M) was added 
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and the solution was heated for an additional minute.  The solution was cooled with 
stirring for 30 minutes then analyzed by UV-Vis spectroscopy.  Two mL of this solution 
was placed on a size exclusion column (300 mg Sephadex G-100 resin in 7 mL water 
prepared in a 9 cm Bio-Rad Poly-Prep polyethylene column) and eluted with 2 mL water.  
The 2 mL of eluent collected had an activity of 12 MBq.  The solution was diluted with 
DPBS to achieve an activity concentration of 1.9 MBq/mL.  Gum arabic particles were 
synthesized as a comparator using the method described in 2.2.2 and similarly 
characterized.   
2.4.4 Bombesin Conjugation 
 Thioctic acid-linked bombesin was synthesized by Dr. Raghuraman Kannan.71   
The thioctic acid-bombesin (3.9 mg) was dissolved in 2 mL ethanol.  Five hundred μL of 
the starch nanoparticles after size exclusion were added to 1 mL of the bombesin 
solution and allowed to stir overnight.  The nanoparticles agglomerated into a pellet 
overnight.  The supernatant was removed and the pellet was washed 3x with 1 mL of 
ethanol to remove any excess bombesin.  The bombesin peptide is soluble in ethanol 
while the nanoparticle-bombesin conjugates are not.  Each washing consisted of 
vortexing, centrifuging, and decanting the remaining supernatant via pipette.  The pellet 
was then washed in a similar manner 3x with 18 MΩ water to remove any unconjugated 
nanoparticles.   
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After washing, particles were analyzed by UV-Vis spectroscopy to confirm a 
change in gold surface environment following the reaction.  The sample was redispersed 
in 500 μL of dimethyl sulfoxide and 1.5 mL of DPBS for a total volume of 2 mL and an 
activity of 9.4 MBq.  The pH of the solution was adjusted to between 7-8 with 1 M NaOH 
and HCl.  Nanoparticles were then diluted with DPBS to achieve the desired activity 
concentration of 1.9 MBq/mL.  
2.4.5 Nanoparticle Characterization 
 Nanoparticles were characterized via UV-Vis spectroscopy as in 2.2.3.  Starch 
nanoparticles were analyzed by radio- thin layer chromatography (TLC) to quantify the 
amount of gold incorporated into the nanoparticle using a Bioscan B-AR-2000-2.  Two μL 
of nanoparticle solution was placed at the bottom of a silica TLC plate and developed in 
methanol with 2 drops of concentrated HCl.  Due to their large size, the gold 
nanoparticles remain at the origin while ionic gold travels up the TLC plate with an Rf of 
0.66.  Synthetic yield was determined from the relative peak areas.  The peaks were 
integrated with the provided WinScan software.  Nanoparticles were analyzed both 
before and after passage through the size exclusion column to confirm the removal of 
unbound gold. 
2.4.6 Biodistribution and Animal Studies 
 Biodistribution studies were performed by Lisa Watkinson and Terry Carmack 
under the supervision of Prof. John Lever and Dr. Jeff Smith at the Harry S Truman 
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Memorial Veterans Affairs Hospital.  Four distinct radioactive agents were injected 
intravenously (I.V.) into SCID mice bearing human prostate tumor (PC-3) xenografts.  PC-
3 cells were obtained from the American Type Culture Collection and cultured by the 
University of Missouri Cell and Immunobiology Core.  Mice were prepared by 
subcutaneous implantation of 10,000,000 PC-3 cells into the right flank.  Solid tumors 
were allowed to develop for 3 weeks.  For the first treatment group, 100 μL of PBS was 
injected I.V. into four mice followed by intraperitoneal (I.P.) administration of 130 kBq 
of 198Au gum arabic gold nanoparticles in 100 μL PBS to determine the biodistribution of 
passively targeted nanoparticles.  An additional four mice received 100 μL of bombesin 
peptide 15 minutes before I.P. administration of 130 kBq of 198Au gum arabic 
nanoparticles in 100 μL of PBS.   
 Starch capped nanoparticles consisted of four different injection groups of five 
mice each.  The first group received 100 μL of PBS I.V. 15 minutes prior to I.P 
administration of 130 kBq of starch capped 198Au nanoparticles in 100 μL of PBS.  Group 
2 received 100 μL of bombesin peptide I.V. 15 minutes prior to an identical nanoparticle 
administration as group 1.  The third group received PBS I.V. 15 minutes before I.P. 
administration of 130 kBq of 198Au starch-bombesin coated nanoparticles in 100 μL of 
PBS.  The final group received I.V. administration of 100 μL bombesin peptide 15 
minutes before I.P. administration of 130 kBq of 198Au starch-bombesin coated 
nanoparticles in 100 μL of PBS.   
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 Additionally, four groups of three mice each received 190 kBq (20 ng) of 64Cu-
bombesin conjugate in 100 μL of PBS.  Group 1 was injected I.V. with 100 μL of PBS 
before conjugate administration I.V.  The second group received 100 μL of bombesin 
peptide I.V. before I.V. conjugate administration.  Group 3 was injected with 100 μL PBS 
before I.P. administration of conjugate.  Finally, group 4 received 100 μL of bombesin 
peptide before I.P conjugate injection.  All mice were sacrificed 2 hours after injection of 
activity and dissected.  Organs and tissue (blood, heart, lung, liver, spleen, large 
intestine, pancreas, and tumor) were collected for analysis by γ spectroscopy.  A 
summary of the injections is presented in Table 2.4.1 
Table 2.4.1: Summary of bombesin injections 
Treatment # of mice Pretreatment Nuclide Activity (kBq) 
Gum arabic NP, I.P. 4 PBS, I.V. 198Au 130 
Gum arabic NP, I.P. 4 Bombesin, I.V. 198Au 130 
Starch NP, I.P. 5 PBS, I.V. 198Au 130 
Starch NP, I.P. 5 Bombesin, I.V. 198Au 130 
Starch-BBN NP, I.P. 5 PBS, I.V. 198Au 130 
Starch-BBN NP, I.P. 5 Bombesin, I.V. 198Au 130 
64Cu-bombesin 3 PBS, I.V. 64Cu 190 
64Cu-bombesin 3 Bombesin, I.V. 64Cu 190 
64Cu-bombesin 3 PBS, I.V. 64Cu 190 
64Cu-bombesin 3 Bombesin, I.V. 64Cu 190 
 
 
 
 
33 
 
2.5 Starch-Bombesin Gold Nanoparticle Results and Discussion  
2.5.1 Starch Gold Nanoparticle Yield and Characterization 
 Starch coated gold nanoparticles showed a UV-Vis absorbance maximum at 544 
nm.  After filtration, the solution showed an absorbance maximum at 541 nm.  During 
the synthesis, a small fraction of starch particles will polymerize, creating long chains of 
linked nanoparticles.  These oligonanoparticles represent the longer wavelength 
absorbance.  After filtration, the absorption maximum decreases in intensity due to 
lower number of particles present and also shifts towards the blue end of the spectrum 
signifying the smaller size of the remaining particles (Figure 2.5.2).  Additionally, ionic 
gold present in the unfiltered sample remains on the sephadex column, as shown in 
Figure 2.5.1 A and B. 
 
Figures 2.5.1 A and B: Radio-TLC of starch coated gold nanoparticles before (A) and 
after (B) filtration.  The origin on each plate is at 50 mm and marked by a red line while 
the solvent front is shown by the line at 95 mm and marked by a blue line. 
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 After conjugation to bombesin, the nanoparticles were washed successively with 
ethanol and water to remove both unconjugated bombesin and free particles.  The 
activity in the supernatant in each wash is shown in Table 2.5.1. 
Table 2.5.1: Activity in each wash of bombesin coated gold nanoparticles 
Wash Activity (kBq) 
Initial supernatant 318 
1st ethanol 44 
2nd ethanol 41 
3rd ethanol 74 
1st water 1890 
2nd water 1300 
3rd water 370 
 
 The ethanol washes were to remove unconjugated peptide and showed small 
activity breakthrough, indicating that very few gold nanoparticles were removed in the 
process.  Water washes, meant to remove nanoparticles without bombesin, showed 
successively decreasing activity in each wash indicating the progressive removal of 
unconjugated nanoparticles.  Removal of both conjugated and unconjugated 
nanoparticles in the wash would remove a constant fraction of activity rather than a 
decreasing amount.  The final nanoparticle solution showed a UV-Vis absorbance of 
0.291 at 561 nm, reflecting the addition of the large bombesin conjugate.  UV-Vis 
Spectra are shown in Figure 2.5.2. 
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Figure 2.5.2:  Shift of the plasmon resonance UV-Vis peak of the nanoparticle after 
starch addition, filtration, and bombesin addition to the surface. 
2.5.2 Gum Arabic Gold Nanoparticle Yield and Characterization 
 The gum arabic gold nanoparticles gave a peak absorbance at 524 nm.  
Nanoparticles were made with 87% yield, as measured by radio-TLC (Figure 2.5.3).   
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Figure 2.5.3: Radio-TLC of 198Au gum arabic gold nanoparticles.  The origin of the TLC 
place is at 50 mm (red line) while the solvent front is at 95 mm (blue line). 
2.5.3 Biodistribution and Animal Studies 
 Injections of 64Cu-bombesin showed expected uptake patterns comparable to 
those previously seen.70   Bombesin targets a GRP receptor subtype which is highly 
expressed in endogenous murine tissue, particularly on the pancreas and large 
intestine.72  As such, these organs are in fact better exemplars of bombesin-specific 
targeting than the tumor xenograft itself.  Human pancreas and large intestine display a 
different GRP receptor subtype which is not targeted by bombesin.  Most of the uptake 
in the 64Cu conjugate occurs in the pancreas and large intestine, indicating targeting of 
GRP receptors.  Further, after blocking with free bombesin peptide, intestinal and 
pancreatic uptake show dramatic, statistically significant decreases (at the 95% 
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confidence level) in both the I.V. and I.P. injection pathways indicating receptor specific 
targeting.  Blocking GRP receptors did not induce a statistically significant change in 
uptake in the tumor xenograft.  Deviations between animals in each injection group are 
small.  Biodistribution data for each organ and injection pathway are shown in Figure 
2.5.4. 
 
Figure 2.5.4:  Blocking studies of 64Cu-bombesin conjugates using both I.V. and I.P. 
injection pathways.  Injecting free bombesin peptide before particle injection produced 
statistically significant differences in pancreatic and intestinal uptake. 
 Passively targeted 198Au gum arabic coated gold nanoparticles exhibit 
biodistribution patterns similar to those observed previously.57  Because the gum arabic 
is tightly bound to the gold nanoparticle, it is not possible to coordinate bombesin using 
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the same chemistry as in the starch nanoparticle case.  Without specific targeting, tumor 
uptake is low after only 2 hours of circulation time.  Nanoparticles are cleared primarily 
through the RES, as evidenced by the large uptake in the liver and spleen.  
Biodistribution data for 198Au gum arabic coated particles is shown in Figure 2.5.5 both 
with and without blocking by unconjugated bombesin peptide. 
 
Figure 2.5.5:  Biodistribution of gum arabic coated gold nanoparticles.  These 
nanoparticles show uptake and clearance typical of passively targeted colloidal systems. 
 Passively targeted starch coated gold nanoparticles mirror uptake observed in 
the gum arabic system.  Primary clearance pathway is through the RES, as evidenced by 
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similar uptake in liver and spleen.  No statistically significant differences in uptake were 
observed by blocking the GRP receptor with excess bombesin.   
 Starch binds less tightly to the surface of gold than gum arabic, and can be 
displaced by a lipoic acid-bombesin conjugate for specific targeting.  Unfortunately, this 
weaker starch binding may also lead to dissociation of the starch from the gold in vivo 
and increased particle aggregation.  Addition of bombesin to the starch nanoparticles 
should increase their uptake by GRP receptors.  Average uptake in the pancreas for the 
starch-bombesin nanoparticles system appears dramatically higher than in the passively 
targeted nanoparticle case, however the large uptake is due primarily to one mouse 
which showed >190% I.D./g.  A Grubbs’ test73 confirmed that uptake in this mouse was a 
statistical outlier, and results for this mouse were disregarded.  After elimination of the 
outlier, the biodistribution data more closely resembles that of gum arabic 
nanoparticles than 64Cu-bombesin conjugates.  The biodistribution data of untargeted 
starch capped nanoparticles and starch-bombesin capped nanoparticles (after 
elimination of the outlier) are shown in Figure 2.5.5 with and without blocking with 
unconjugated bombesin peptide.  Differences between the four groups showed no 
statistical significance after removal of the outlier.   
 Previous reports indicated that starch-bombesin capped gold nanoparticles 
exhibited specific, receptor-mediated uptake both in vitro and in vivo.74  In vitro, the 
nanoparticles show variable IC50 values against GRP receptor, from 8.10 ± 0.30 µg/mL 
for low bombesin loading to 2.45 ± 0.18 µg/mL for high bombesin loading.71  The study 
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did not include controls of starch-coated gold nanoparticles, therefore no conclusions 
can be made about the specificity of the nanoparticle system despite its high affinity for 
the GRP receptors.   
 
Figure 2.5.5: Biodistribution of starch capped gold nanoparticles.  These nanoparticles 
show biodistribution and clearance through the RES system.  Actively targeted starch-
bombesin capped nanoparticles show no significantly different uptake in vivo.  
 Error bars in the in vivo experiments show wide variability in pancreatic uptake 
consistent with a single outlier that was not excluded.  While the 64Cu-bombesin 
conjugate confirms that bombesin can be an effective targeting agent for the GRP 
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receptor, bombesin was ineffective in the starch-capped gold nanoparticle system.  
While there is variance in starch size based on the plant source, potato starches tend to 
consist of a 24-30 glucose oligomer chain.75  Given the large size of the nanoparticle 
surfactant and the small size of the linker (a 5 carbon chain from lipoic acid), the 
targeting portion of bombesin may have been covered by the starch and not exposed to 
GRP receptors in vivo.  Lipoic acid-bombesin conjugates do not fully displace the starch 
surfactant, but merely attach to the surface displacing a portion of the attached starch.  
The remaining starch molecules may sterically hinder bombesin-GRP receptor 
interactions, blocking the specific targeting.  Additionally, the amino acids of the 
bombesin peptide may interact with the starch molecules themselves, further 
decreasing the amount of targeting sequences accessible to GRP receptors.  It is unlikely 
that the bombesin separates from the nanoparticles as the nanoparticles do not revert 
to their pre-conjugation solubility.  Additionally, a change in the UV-Vis absorbance 
would appear after dissociation, which is not observed.  Another potential explanation 
for the poor in vivo targeting is rapid clearance of the nanoparticles through the RES.  
The bombesin conjugates do not circulate for a sufficient time to bind to the GRP 
receptor, which would explain the discrepancy between the high in vitro binding and the 
low in vivo binding. 
 Future experiments should focus on the effect of different bombesin conjugation 
approaches on GRP receptor uptake.  Longer polyethylene glycol (PEG) linkers are 
available from a variety of sources, and can easily be linked to the peptide.  Other, less 
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bulky and easily displaced surfactants are also available.  The citrate reduction of the 
Turkevich procedure creates biocompatible nanoparticles that can be further 
functionalized with lipoic acid linkages.  Citrate-capped nanoparticles are unstable 
towards aggregation in vivo, however, they can be passivated by addition of a PEG 
group linked to lipoic acid.76  An alternative system would utilize a citrate capped gold 
nanoparticle linked to a commercially available lipoic acid-PEG-COOH linker.  The 
bombesin peptide would then be attached via 1-Ethyl-3-(3-
dimethylaminopropyl)carbodiimide (EDC)/sulfo N-hydroxy succinimide (NHS) 
chemistry.49 
 
2.6 64Cu-DTDTPA Gold Nanoparticle Experimental 
2.6.1 Materials and Measurements 
 All chemicals were at least ACS grade and purchased from Sigma-Aldrich and 
used as received unless otherwise noted.  High purity (>18 MΩ) water was produced 
from an in-house generator.  TEM images were obtained on a JEOL 1400 transmission 
electron microscope (JEOL Ltd, Tokyo, Japan). TEM samples were prepared by placing 5 
µL of gold nanoparticle solution on a 300 mesh carbon-coated copper grid and allowing 
the solution to stand for five minutes. Excess solution was removed carefully and the 
grid was allowed to dry for an additional five minutes. The average size and distribution 
of the gold nanoparticles synthesized were determined by the processing of the TEM 
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image using Adobe Photoshop (with Fovea plugins).  The hydrodynamic diameter and 
the zeta potential were obtained using a Zetasizer Nano S90 (Malvern Instruments Ltd. 
USA) using a dilute (0.08 g/L) aqueous solution.  The UV-Vis absorption spectra were 
recorded at room temperature using Varian Cary 50 UV/Vis spectrophotometers. The 
absorption measurements were performed on dilute colloidal gold nanoparticle solution 
in disposable cuvettes with a 10 mm path length.  Estimation of gold concentration in 
conjugates was performed using furnace atomic absorption spectroscopy (AAS) with a 
standard curve spanning 0–40 µg/L (Perkin–Elmer AAnalyst 800 ThGA graphite furnace). 
Quality-control materials (duplicates, spikes, and instrument-calibration verification) 
were within appropriate ranges.  Dithiolated diethylene triamine pentacetic acid 
(DTDTPA) and nanoparticle synthesis, characterization, and cell studies were performed 
by Dr. Ajit Zambre (sections 2.6.2-2.6.5 and 2.6.9).  Radiolabeling, radiostability, 
radiosynthesis, and data analysis for animal studies were performed by Mark 
McLaughlin (sections 2.6.6 – 2.6.8).  Biodistribution and animal studies were performed 
by Lisa Watkinson and Terry Carmack under the supervision of Prof. John Lever and Dr. 
Jeff Smith at the Harry S Truman Memorial Veterans Affairs Hospital (section 2.6.10). 
2.6.2 DTDTPA Synthesis 
DTPA (0.78 g), acetic anhydride (0.75 mL) and anhydrous pyridine (1.02 mL) were 
mixed and heated to 70C for 18 hrs in a 5 mL glass V-bottom vial.  The resultant 
mixture was cooled to room temperature and further chilled to 4C.  The precipitate 
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was collected by filtration, purified by repeated washing with acetic anhydride followed 
by anhydrous ether.  The washed precipitate was filtered and dried under vacuum to 
obtain 0.63 g, 91% of DTPA-bisanhydride (DTPA-BA).77 
DTPA-BA (0.5 g, 5.6 x 10-3 mol) was dissolved in 10 mL of dimethylformamide 
(DMF) in a 100 mL round bottom flask with constant heating at 70C.  Aminoethanethiol 
(0.25 g, 1.23 x 10-2 mol) was dissolved separately in another flask with 8 mL of DMF and 
0.44 mL of triethylamine.  This solution was then added to the round bottom flask 
containing DTPA-BA with constant stirring and the reaction mixture was heated to 70C 
overnight.  Subsequently, the reaction mixture was cooled to room temperature and 
placed in an ice bath.  The resulting white residue (triethylamine hydrochloride) was 
filtered.  The filtrate was then concentrated at reduced pressure and further mixed with 
chloroform to form a white precipitate.  This precipitate was filtered and washed 
thoroughly with chloroform to remove impurities.  The precipitate was dried under 
vacuum to obtain white DTDTPA (0.49 g, 86%) and characterized by nuclear magnetic 
resonance (NMR).78 
 
Figure 2.6.1:  Structure of DTDTPA. 
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2.6.3 Synthesis of DTDTPA Gold Nanoparticle Conjugates  
DTDTPA functionalized nanoparticles were prepared by dissolving 200 mg (5.1 x 
10-5 mol) of HAuCl4.3H2O in 120 mL of methanol in a 500 mL round bottom flask.  In a 
separate flask, 482 mg (9.4 x 10-5 mol) of DTDTPA was dissolved in 40 mL of methanol 
and 2 mL of glacial acetic acid.  This solution was added with continuous stirring to an 
aqueous solution of gold salt to produce an orange solution.  To this mixture, 190 mg (5 
mmol) of NaBH4 dissolved in 14 mL of water was added under vigorous stirring at room 
temperature.  Immediately after addition of NaBH4, the solution became dark brown 
followed by appearance of black flocculate.  The resultant mixture was allowed to stir 
for 1 hour at room temperature before addition of 5 mL of 1M HCl.  This black solution 
of gold nanoparticles was then centrifuged at 7000 RPM for 20 minutes.  The 
supernatant was removed and the particles were washed twice with 0.01 M HCl, using 
the same centrifugation parameters.  The particles were further washed successively 
with water followed by diethyl ether.  The resulting black powder of Au nanoparticle-
DTDTPA was dried under vacuum and stored at -20oC. As needed, the particles were 
readily dispersed in 0.01 M NaOH and were stable against aggregation for over a month 
as determined by UV-Vis spectroscopy.  
2.6.4 Chelation of Cu2+ with Gold-DTDTPA Nanoparticles 
Copper was added to Au-DTDTPA at room temperature with continuous stirring.  
A 5 mL solution of 10 mg/mL Au-DTDTPA was prepared by dissolving nanoparticles in 5 
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mL of 1 M NaOH, then neutralized to pH = 7.0 with 1 M HCl.  Ten mg of CuCl2 was added 
to this solution with continuous stirring.  The formation of precipitate was immediately 
observed.  The reaction mixture was stirred for 5 minutes to produce a brownish black 
residue which was collected by centrifugation. The residue was washed with deionized 
(DI) water thoroughly to remove any unreacted copper salt and dried under vacuum.  
The amount of copper required to saturate the chelate was monitored by titrimetric 
analysis utilizing atomic absorption spectroscopy.   
2.6.5 Titrimetric Analysis of Copper on Gold-DTDTPA Nanoparticles: 
The amount of Cu2+ ions required for complete saturation of Au-DTDTPA was 
determined by AAS measurements.  The titration was performed by successive addition 
of an aqueous solution of CuCl2 (2 mg - 30 mg) to 10 mg of colloidal Au-DTDTPA 
dispersion at room temperature with continuous stirring.  After the reaction was 
complete the reaction mixtures were collected in individual centrifuge tubes and 
centrifuged at 5000 RPM for 5 minutes.  The pellets were resuspended in DI water, 
centrifuged, and the supernatants decanted.  All the supernatants and pellets were 
analyzed for copper content by AAS. 
2.6.6 64Cu Isotope Production and Specific Activity Analysis 
Targets were irradiated as previously described79 by Tom Brossard using 
approximately 12 MeV protons on a GE PETtrace cyclotron at MURR with a 99% 
enriched 64Ni target.  Isotope yield measurements were determined using either a γ 
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spectrometer (Canberra model 1510, Meriden, CT) and/or a radioisotope dose 
calibrator (Capintec CRC-10, Pittsburgh, PA).  The γ spectrometer was used to detect 
radionuclidic impurities.  Specific activities were determined as described previously for 
64Cu by titration of 64CuCl2 with the macrocyclic chelator TETA.
79  Briefly, aliquots of 
varying amounts of TETA were added to 64Cu and the complexation yield monitored by 
radio-TLC.  The samples were spotted on C-18 plates and the plates developed using 1:1 
methanol:10% ammonium acetate with two drops of concentrated HCl.  CuCl2 remains 
at the origin whereas complexed copper in the form of Cu(TETA)2- migrated with Rf = 
0.9. The minimum TETA concentration for which 100% labeling occurred was assumed 
to be equal to the concentration of Cu+2 present. 
2.6.7 Radiochemical Synthesis of 64Cu Gold-DTDTPA Nanoparticles 
Five mg of Au-DTDTPA was dissolved in 500 µL of 1 M NaOH to give a 10 mg/mL 
solution.  This solution (20 µL) was added to 750 µL of a buffer solution consisting of 0.4 
M ammonium acetate adjusted to pH = 4 using HCl and sonicated for 30 minutes.  
Radioactive 64CuCl2 (MURR cyclotron facility, 81 MBq) was received in 150 µL of 0.1 M 
HCl.  Forty-five µL of 64CuCl2 (27 MBq) was added to the Au-DTDTPA/buffer solution and 
placed in a boiling water bath for 30 minutes.  Unlabeled copper was removed from 
solution by eluting the labeled nanoparticles through a chelex 100 cation exchange resin 
(Bio Rad) column with 18 MΩ water.  The column was prepared by dispersing 300 mg of 
resin in 7 mL of water and depositing the slurry in a Bio Rad Poly-Prep 9 cm column.  
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Excess liquid was allowed to pass through the slurry and the prepared column was then 
washed twice with 2 mL of PBS.  The nanoparticle solution (1.25 mL) was loaded onto 
the column and eluted with 5 mL of PBS.  The effluent and column were counted on a γ 
spectrometer using the 511 keV peak to determine labeling yield.  Nanoparticle solution 
was adjusted to pH = 7.5 using NaOH and HCl, then diluted to a volume of 2.5 mL using 
PBS.   
2.6.8 In Vitro Stability of Gold-DTDTPA and 64Cu Gold-DTDTPA Nanoparticles 
In vitro stability studies of 64Cu-Au-DTDTPA were performed by challenging 0.5 
mL of 64Cu-Au-DTDTPA with water, PBS, cysteine, or rat serum albumin (RSA). 
Nanoparticle conjugates were synthesized as in 2.6.7 using 5 µL of 10 mg/mL 
nanoparticles in 495 µL of water.  Each of these solutions then received ~17 MBq of 
64CuCl2.  Addition of 500 mL of water, 2x PBS, 0.2 M cysteine, or 0.2 M RSA gave final 
concentrations in each vial of PBS or 0.1 M.  The stability was measured by monitoring 
the UV-visible absorbance and radio-TLC at 0, 24, and 48, and 120 hours.  Radio-TLC was 
performed with C18 plates (Whatman) in a developing solution of 1:1 by volume 
solution of methanol:10% ammonium acetate. 
2.6.9 In Vitro Cytotoxicity Measurements  
In vitro cytotoxicity was evaluated using a 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) cell proliferation assay kit (Promega Corporation).  
Cells at the exponential growth phase (1x105 cells/mL) were placed in a flat-bottom 96-
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well polystyrene-coated plate and incubated in a CO2 incubator at 5% CO2 and 37 C for 
24 hours.  A series of concentrations (0, 1, 2.5, 5, 10, 20 and 40 µg/mL) of Au-DTDTPA 
and Cu-Au-DTDTPA were added to wells in quadruplet.  After incubation for an 
additional 24 hours, 10 μL MTT (5 mg/mL in PBS) was added to each well and kept for 24 
hours.  Formazan crystals produced by living cells were dissolved in 100 μL of 
isopropanol added to each well plate and kept in the dark at 25°C for 18 hours.  The 
intensity of developed color was measured by micro plate reader (Dynastic MR 5000) 
operating at 570 nm wavelength. Wells with complete medium, nanoparticles, and MTT, 
but without cells, were used as blanks. Untreated cells were considered 100% viable.  
2.6.10 In Vivo Biodistribution Measurements  
 Biodistribution and animal studies were performed by Lisa Watkinson and Terry 
Carmack under the supervision of Prof. John Lever and Dr. Jeff Smith at the Harry S 
Truman Memorial Veterans Affairs Hospital.  Evaluation of pharmacokinetics of 64Cu-Au-
DTDTPA was conducted in normal CF1 mice.  Nanoparticle conjugates (1.48 MBq in 100 
µL of PBS) were injected via the tail vein (n=3).  Animals were sacrificed at 0.25, 0.5, 2, 4, 
and 24 hours post injection by cervical dislocation.  The following organs were collected 
for measurement on a well counter: tail, blood, heart, lung, liver, spleen, stomach, large 
intestine, small intestine, kidney, urine, feces, muscle, bone, bladder, brain, pancreas, 
and carcass. 
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2.7 64Cu Gold-DTDTPA Results and Discussion 
 Au-DTDTPA nanoparticles fail to show an absorption maximum associated with 
the plasmon resonance.  The spectrum shows a small absorption hump around 525 nm 
that corresponds with the expected plasmon resonance peak in both the Au-DTDTPA 
nanoparticles and the Cu-Au-DTDTPA nanoparticles.  These absorption spectra are 
shown in Figure 2.7.1.80 
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Figure 2.7.1 A and B: UV-Vis absorption spectra of Au-DTDTPA (A) and Cu-Au-DTDTPA 
(B). 
 TEM analysis shows that the nanoparticles have a metallic diameter of ~3 nm.  
Some variability is present, with nanoparticles as large as 20 nm in diameter.  This size is 
typical of nanoparticles made via the Brust procedure.28  Figure 2.7.2 shows a 
characteristic TEM of the nanoparticles.   
B A 
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Figure 2.7.2: TEM showing a characteristic Au-DTDTPA nanoparticle dispersion 
 Hydrodynamic diameter and zeta potential are shown in Table 2.7.1.  The large 
hydrodynamic diameter relative to the small metallic diameter is also expected.  Zeta 
potential values that are highly positive or negative indicate the nanoparticles should be 
stable towards aggregation.81  The saturation curve as measured by AAS is shown in 
Figure 2.7.3.  At low levels of added copper, synthetic yield is constant.  Addition of 
more than 4.72 mg of copper saturates the 10 mg of Au-DTDTPA used and leads to 
decreasing yield.  This saturation was confirmed using radio-TLC and 64Cu.   
Table 2.7.1: DLS properties of Au-DTDTPA and Cu-Au-DTDTPA 
Construct Hydrodynamic Diameter (nm) Zeta Potential (mV) 
Au-DTDTPA 133.6 -40.63 
Cu-Au-DTDTPA 149.3 -55.06 
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Figure 2.7.3: Copper saturation of Au-DTDTPA as measured by AAS 
 Cu-Au-DTDTPA nanoparticles monitored in water, PBS, and rat serum show 
constant plasmon resonance peak location and intensity as monitored by UV-Vis 
spectrometry.  The constant peak indicates that the nanoparticles are stable towards 
aggregation.  Nanoparticles monitored in cysteine show a consistent wavelength of 
maximum absorption, but decreased absorption intensity over the monitoring period.  
The peak completely disappears by 120 hours.  Cysteine contains a sulfur side chain, 
which can displace the thiolated DTDTPA chelating agent from the surface of the gold 
nanoparticle.  Without the protection provided by the DTDTPA ligand, the nanoparticles 
likely aggregate and the plasmon resonance peak disappears.  Figure 2.7.4 shows the 
decrease of the Cu-Au-DTDTPA plasmon resonance over time. 
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Figure 2.7.4: Stability of Cu-Au-DTDTPA in cysteine.  UV-Vis spectroscopy of Cu-Au- 
shows decrease in plasmon resonance over time, ultimately disappearing at 120 hours. 
 Radio-TLC measurements indicate the same process.  Initially, radio-TLC shows 
one large peak at the origin for Cu-Au-DTDTPA samples in each biological mimic 
solution.  Over time, an increasing amount of activity is seen in the cysteine solution at 
an Rf of 0.2, indicating that the activity is being displaced from the gold nanoparticle.  
After 96 hours, roughly half of the activity has been displaced from the particle surface.  
Because of the stability of the Cu-DTDTPA complex, we conclude that the loss of activity 
is indicative of the loss of chelate from the Au nanoparticles. Figures 2.7.5 A and B show 
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a characteristic radio-TLC and the cysteine solution radio-TLC after 96 hours, 
respectively. 
 
 
Figure 2.7.5 A and B: Stability studies of 64Cu-Au-DTDTPA via radio-TLC.  These 
chromatograms are characteristic of 64Cu-Au-DTDTPA in water/PBS/rat serum (A) and 
after 96 hours in cysteine (B).  Activity travels up the TLC plate as the chelate is displaced 
from the nanoparticles.  The origin is at 50 mm and the solvent front at 100 mm. 
A 
B 
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 While the instability in cysteine solution is troubling, significant dissociation only 
occurs at high concentrations of cysteine and after multiple half-lives of 64Cu.  
Mammalian levels of cysteine typically vary from 20-100 µM82 whereas the nanoparticle 
conjugate was challenged with a solution of 0.2 M cysteine.  After ~8 half-lives (96 
hours), 50 % of the activity remains bound to the gold nanoparticles.  While an ideal 
construct would exhibit no dissociation, the nanoparticles are likely stable enough to 
warrant further study.  First, the concentration of cysteine used to test stability is over 
1,000 times higher than what is observed in vivo.  Lower concentrations of cysteine will 
likely cause less significant dissociation.  As imaging times with 64Cu are often on the 
order of 24-48 hours,83 the stability of our complex after 48 hours warrants further 
study.  
 In vitro cytotoxicity measurements with SKBr3 breast cancer cells indicate that 
the Au-DTDTPA nanoparticles are well tolerated at low concentrations.  However, above 
10 μg/mL, cells showed decreased survivability relative to controls.    Figure 2.7.6 shows 
the effect of Au-DTDTPA and Cu-Au-DTDTPA on breast cancer cells. 
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Figure 2.7.6: Cell viability studies of breast cancer SKBr3 cells 
 Nanoparticles prepared for biodistribution studies were labeled with a chemical 
yield of 94% as determined by activity load on the cation exchange column.  Unbound 
64CuCl2 was completely retained on the column.  In vivo, the 
64Cu-Au-DTDTPA showed 
uptake consistent with passively targeted nanoparticle constructs.  Initially, activity 
appears primarily in the liver, then decreases as the nanoparticles are cleared through 
the RES or hepatobiliary system and are excreted in the feces.  Approximately 1/3 of the 
injected activity clears through the feces after 24 hours.  Activity present in the kidney 
likely represents 64Cu-DTDTPA, as the nanoparticle construct itself is likely too large to 
enter the glomerular filtrate and over 95% of free 64Cu binds proteins found in serum.84   
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Figures 2.7.7 A and B:  Uptake of 64Cu-Au-DTDTPA nanoparticles as %ID/organ (A) and 
%ID/g (B).  Biodistribution shows uptake similar to untargeted, gum arabic coated 
nanoparticles. 
B 
A 
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Additionally, the negative charge on the nanoparticle further limits filtration and urine 
excretion.85  Figures 2.7.7 A and B show uptake as %ID/organ and %ID/g, respectively. 
  Stability of the 64Cu-Au-DTDTPA nanoparticle system under the observed 
conditions is inconclusive.  While nanoparticles are expected to clear via the RES and 
hepatobiliary system, free 64Cu also clears via the hepatobiliary system with excretion in 
the feces after 24 hours.86  The large uptake in the liver could indicate uptake through 
either of these routes.  Uptake in the spleen, primarily due to RES clearance, is lower 
than in the case of the passively targeted gum arabic gold nanoparticles.  This difference 
could be explained by a number of factors, including partial dissociation of 64Cu from 
DTPA or differences in nanoparticle surface charge, size, or hydrophilicity.   
 A dual label experiment would conclusively determine the stability of the 64Cu-
DTDTPA-nanoparticle conjugate.  Comparing the biodistribution of gold nanoparticles 
synthesized from 198/199Au and the attached 64Cu-DTDTPA would establish the viability of 
the system.  Similar biodistributions for 64Cu and 198/199Au indicate that the conjugate 
remains largely intact while significantly different biodistributions indicate that the 64Cu 
does not remain attached to the nanoparticle in vivo.  If the system is stable, it would 
warrant future study.  The small size of the nanoparticles indicates they may show high 
tumor uptake via the EPR effect.87  Finally, specific targeting agents such as bombesin 
could be added to target a particular type of tumor rather than relying on passive 
uptake. 
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CHAPTER 3: 
GOLD SHELL NANOPARTICLES FOR in vivo 225Ac α-GENERATOR 
 
 
3.1 Chemistry of 225Ac and the Lanthanides 
 Chemical interest in the actinides focuses primarily on their wide variety of 
oxidation states and unique f-orbital interactions.  These properties of actinides give 
them a wide range of colors and facilitate their use as catalysts.88  Despite also filling f-
orbitals, the lanthanide series shows much less oxidation state variety.  All of the 
lanthanides primarily form the 3+ oxidation state, with the exception of Ce, which also 
easily forms the 4+ state.89  As the first actinide, the electronic structure of Ac does not 
heavily populate the 5f orbital.  Because of this, its chemical behavior more closely 
resembles the lanthanides rather than the rest of the actinide series.  Actinium easily 
loses three electrons to form the 3+ oxidation state.   
 Additionally, relativistic effects further contribute to the similarity between Ac 
and the lanthanides, in particular the early lanthanides.  Due to relativistic effects, the 
atomic radii of Ac (in particular the s shells) are more contracted than what would 
otherwise be expected.  Therefore, the difference in size between Ac and La is smaller 
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than indicated by non-relativistic size calculations.  These relativistic effects are also 
responsible for the surprising stability of high oxidation states found in many of the 
actinides.90 
 Previous studies incorporated 225Ac into LaPO4 nanoparticles by a process of 
precipitation from organic solution.  Phosphates of the lanthanides are highly insoluble 
in water, with pKsp values ranging from 25.51 (Nd) to 26.57 (Sm).
91  Ions of La3+ and 
225Ac3+ mixed with phosphoric acid produce a precipitation of monodisperse 
nanoparticles with 44% radiochemical yield.  This particle system is capable of retaining 
~50% of the 221Fr daughter and 99.9% of the 225Ac parent.48  Conjugation to biological 
targeting agents occurs via an ionic linkage between 6-aminohexanoic acid and surface 
phosphate.  Unfortunately, the complex synthesis involves inert atmosphere conditions 
and reproducibility issues.  Presumably, the ionic linkage remains stable in the aqueous 
in vivo environment due to the association of residual organic compounds with the 
surface of the nanoparticle.  An aqueous synthetic pathway, which could reliably be 
used under normal atmospheric conditions, would be desirable. 
  
3.2 Nanoparticle Synthesis and Characterization Experimental 
3.2.1 Materials and Equipment 
 All chemicals were used as received from Sigma-Aldrich unless otherwise noted 
and were ACS grade or higher.  Water used was purified using an in house purification 
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system to 18 MΩ or higher.  Radioactivity measurements were performed with a γ 
spectrometer consisting of a high purity germanium detector and a Canberra Industries 
multichannel analyzer.  Full width at half maximum resolution of the detector was 0.7 
keV at 218.2 keV. Detector dead times were typically <1% and count rates were 
automatically corrected for the detector dead time by the γ spectroscopy software. A 
regenerated cellulose dialysis membrane with a 10 kDa molecular weight cutoff 
(MWCO, Spectra/Por, 128106) was used to purify nanoparticle dispersions.  The dialysis 
membrane was washed of preservatives with 18 MΩ water before dialysis against 18 
MΩ water.  A 0.4 T NdFeB magnet (Supermagnet #31, United Nuclear) was used for 
magnetic separation of Gd containing nanoparticles from solution.  Nanoparticles were 
characterized by TEM (JEOL 1400), NAA, x-ray diffraction (XRD, Scintag X2), and electron 
energy loss spectroscopy-TEM (EELS-TEM, Zeiss Libra 120).  All 225Ac processes were 
performed at Oak Ridge National Laboratory. 
3.2.2 Purification of 225AcCl3 
 Actinium-225 chloride was prepared as previously described from a stock of 
229Th.92  Briefly, 225Ra and 225Ac are separated from the parent 229Th using two columns 
of MP1 (Bio-Rad Laboratories) anion exchange resin in sequence with 8 M HNO3.  The 
225Ac is further separated from 225Ra using two sequential columns of AG50-X4 cation 
exchange resin.  Radium was eluted with 1.2 M HNO3 while 
225Ac was eluted with 8 M 
HNO3.  Separated 
225Ra was reprocessed as needed to provide additional 225Ac.  
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Actinium separation was performed by Dr. Rose Boll and Karen Murphy at Oak Ridge 
National Laboratory. 
 Samples of 225Ac in 1.2 M HNO3 were evaporated to dryness on a hot plate with a 
continuous flow of air in a V-bottom vial.  The dried salt was redispersed in 1 M HCl and 
evaporated to dryness under the same conditions.  Finally, the sample was redispersed 
in 0.1 M HCl and transferred to a 1 mL V-bottom vial for synthesis. 
3.2.3 Synthesis of {LaxGd1-x}PO4 nanoparticle cores 
Lanthanide phosphate nanoparticles were made by modifying a methodology 
developed by Buissette et al.93  Briefly, aqueous solutions of 0.1 M LaCl3∙7 H2O and 
GdCl3∙6 H2O were mixed in a 1 mL V-bottom vial with magnetic spin vane.  The amount 
of La and Gd added was varied to give {LaxGd1-x}PO4 nanoparticles where x = 0, 0.25, 0.5, 
and 1 with a total addition volume of 100 μL.  For biological preparations, ~190 MBq of 
225AcCl3 in 50 μL 0.1 M HCl was added to the lanthanide mixture.  Preparations for in 
vitro retention measurements and yield studies used 7.4-9.3 MBq of 225Ac.  Preparations 
for characterization purposes were synthesized without 225Ac addition.   
Next, 200 µL of 0.1 M sodium tripolyphosphate (TPP) was added to give a clear, 
colorless solution with a Ln:Na-TPP molar ratio of 1:2.  If the solution remained turbid 
after addition of Na-TPP, it was aspirated with small (10 μL) additions of Na-TPP until 
the solution appeared clear.  The resulting solution was then capped and heated at 90oC 
for 3 hours in a Thermo-Scientific heat bath with a custom made aluminum heat block.  
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The resulting turbid, white solution of nanoparticles was transferred into a 10 kDa 
dialysis tube and purified against 18 MΩ water overnight.  The nanoparticles were 
removed via pipette, producing 2.4 mg of monodisperse particles of ~4 nm diameter 
which were characterized by TEM, NAA, and XRD. 
3.2.4 Layering of {LaxGd1-x}PO4 nanoparticles 
 Layers of LnPO4 were added to the crystalline nanoparticle cores by a process of 
oriented attachment.  Nanoparticle cores were collected in a 1.5 mL microcentrifuge vial 
centrifuged at 3,000 g for 3 minutes.  The supernatant was decanted via pipette, and 
nanoparticles were redispersed into a solution containing 400 μL 0.05 M Na-TPP with 
0.05 M LaCl3 and/or 0.05 M GdCl3.  Lanthanides were added to give layer composition of 
{LaxGd1-x}PO4 where x = 1, 0.5, or 0 in a total volume of 200 μL.  This nanoparticle 
suspension was then sonicated for 10 minutes in a bath sonicator, vortexed, and heated 
for an additional 3 hours in a capped 1 mL V-bottom vial at 90oC to add a layer of LnPO4.  
The layering procedure was repeated to deposit two or four layers of LnPO4 on top of 
the core nanoparticle.  The final thick, white solution of nanoparticles was then purified 
by dialysis overnight against 18 MΩ water. Non-radioactive analogs of the nanoparticles 
were characterized by EELS-TEM and NAA.   
3.2.5 Gold Shell Addition 
 Dialyzed LnPO4 nanoparticles (~12 mg) were evenly divided between three 5 mL 
V-bottom vials (4 mg each) with spin vanes.  Next, 300 µL of 0.1 M sodium citrate was 
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added to each vial followed by enough 18 MΩ water to bring the final volume to 2 mL.  
The vials were then sonicated for 10 minutes in a bath sonicator and heated to 90oC.  
Over the course of 25 minutes, 2.5 mL of 1 mM NaAuCl4 (ph = 4) was added dropwise, 
during which time the solution turned the deep purple-red color associated with gold 
nanoparticles.  The solution was heated uncapped for an additional 30-45 minutes and 
cooled to room temperature.  The gold coated nanoparticles were placed next to the 
NdFeB magnet overnight for separation.  The supernatant was decanted via pipette and 
magnetically active nanoparticles collected for further analysis.  Both supernatant and 
separated particles were counted on a γ-spectrometer after establishment of 
equilibrium to determine separation yield.  Figure 3.2.1 shows a purified sample of gold 
coated nanoparticles following magnetic separation.   
 In this dissertation, nanoparticle compositions consisting of a core of varying 
amounts of lanthanide phosphates will be presented with the cation fraction in braces 
followed by the counteranion.  If a radioactive dopant is present, it will be presented in 
parentheses.  For example, a half LaPO4, half GdPO4 nanoparticle core with an 
225Ac 
dopant will be presented as {La0.5Gd0.5}(
225Ac)PO4.  Additionally, other layers are named 
using the convention core@shell.  Antibodies or linkers attached to the gold surface will 
be named with a dash followed by the antibody or linker.  Thus, a nanoparticle with the 
aforementioned core, four shells of a lanthanide phosphate, an exterior gold layer, and 
monoclonal antibody (mAb) 201b antibody would be named {La0.5Gd0.5}(
225Ac)PO4@4 
LnPO4@Au-mAb 201b.   
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Figure 3.2.1: {La0.5Gd0.5}(
225Ac)PO4@4 GdPO4@Au nanoparticles after overnight 
magnetic separation 
3.2.6 Layering Yield Measurements 
 La-140 and 159Gd radiotracers were produced at MURR, employing the 
pneumatic tube irradiation facility.  La(NO3)3∙6 H2O (5.8 mg) was irradiated for 15 min, 
generating ~ 28.7 MBq of 140La.  Similarly, 2.31 MBq of 159Gd was produced by 
irradiating 6.2 mg of Gd(NO3)3∙6 H2O for 45 minutes.  {La0.25Gd0.75}PO4 nanoparticles in 
solution as synthesized in 3.2.3 were centrifuged and the supernatant removed.  They 
were redispersed in 400 μL of 0.05 M HCl containing radiotracer 140La and transferred to 
66 
 
a 5 mL V-bottom vial.  Na-TPP (800 μL, 0.05 M) was added and the solution heated in a 
capped vial for 3 hours at 90oC, the layered nanoparticles were moved to a liquid 
scintillation vial and placed by a NdFeB magnet for separation overnight.  Following 
separation, the supernatant fraction opposite the magnet was decanted via pipette and 
collected.  The supernatant and the nanoparticle fractions were counted on a γ 
spectrometer using identical geometries to determine the fraction of 140La in each 
component.  Nanoparticle composition of gold-coated analogs was measured via NAA at 
MURR to confirm layering yield.  Briefly, three samples of 10 µL of nanoparticles were 
dried down in a 2/5 dram polyethylene vial.  Vials were heat sealed, then irradiated for 
15 seconds, and allowed to cool for 1 minute.  The composition of the 
{Gd0.75La0.25}PO4@4 LaPO4 shells@Au layered nanoparticles was determined by standard 
comparator NAA using 140La (10 µg), 159Gd (10 µg), and 198Au (1 µg). Standards were 
irradiated with the samples in the pneumatic tube system at MURR (neutron flux = of 
8*1013 n/cm2/s) for 15 seconds.  Each sample was allowed to decay for 60 seconds, then 
counted for 30 seconds on a high purity germanium detector.   
Layering efficiency of GdPO4 was determined similarly using 
159Gd radiotracer.  
Because the magnetic properties of Gd preclude magnetic separation of layered and 
non-layered GdPO4 nanoparticles, the layered nanoparticles were allowed to 
precipitate.  The supernatant was decanted via pipette and the activity of the 
nanoparticles and supernatant were measured on a γ spectrometer.  Gd yield was 
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confirmed by measuring the ratio of Gd:La in the {Gd0.5La0.5}PO4@4 GdPO4 shell@Au via 
NAA and comparing to the theoretical ratio. 
3.2.7 In Vitro Stability Studies 
 {La0.5Gd0.5}PO4@4 GdPO4@Au nanoparticles with PEG surface functionalization 
(3.4.2) were monitored for their stability against aggregation in vitro using UV-Vis 
spectroscopy.  Samples (0.5 mg) were kept in 1 mL of either DI water, PBS, or BSA for 
one month.  The absorption was measured from 350-700 nm three times a week to 
determine stability of both the wavelength and intensity of the surface plasmon 
resonance band.   
3.2.8 In Vitro Retention Testing 
 Retention of the 225Ac decay products was quantified in vitro via dialysis.  The 
225Ac nanoparticles (14 mg) were placed in a dialysis tube and suspended in 400 mL of 
18 MΩ water.  The dialysis tube was allowed to equilibrate for at least 3 hours (four 
half-lives of the longest lived α-emitting daughter, 213Bi), before the initial measurement 
and between each subsequent measurement.  A 5 mL aliquot of the dialysate was taken 
for radioactivity measurement each day over the course of 20 days (two 225Ac half-lives).  
Each dialysate sample was counted immediately to determine 221Fr leakage via the 213Bi 
activity and then re-analyzed the following day to determine the level of 225Ac in the 
aliquot using the 221Fr peak.  Counts were corrected for decay during sample transport, 
decay during the counting period, and the decreasing dialysate volume throughout the 
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monitoring period.  The corrected activity was compared to the level of 225Ac activity at 
the time of separation to determine the 221Fr and 225Ac retention.  Both the 218 keV γ 
ray from 221Fr and the 440 keV γ ray from 213Bi were used to determine 221Fr retention.  
Because 213Bi does not move across the dialysis membrane,48 all of the 213Bi in the 
dialysate originates from decay of  221Fr present in the dialysate.   
 
Figure 3.2.2: {La0.5Gd0.5}(
225Ac)PO4@4 GdPO4@Au nanoparticles loaded into 10 kDa 
MWCO membrane for in vitro daughter retention studies 
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3.2.9 Layer Leaching Studies 
 Nanoparticles cores were synthesized as in 3.2.3.  One shell of either 159GdPO4 or 
140LaPO4 was added as in 3.2.4 using radiotracers produced as described in 3.2.6.  The 
nanoparticles were placed in a dialysis membrane and dialyzed for three hours against 1 
L of 18 MΩ water.  The dialysate was then removed and replaced with a new 1 L of 
water.  Nanoparticles were dialyzed overnight, then counted on a γ spectrometer.  
Twenty mL of the dialysate was also collected and counted.  The dialysate count was 
corrected for dilution and counting time then compared to the particle activity. 
3.2.10 XRD Studies 
 Nanoparticles for XRD studies were prepared as in 3.2.3 with compositions of 
LaPO4, {La0.25Gd0.75}PO4, {La0.5Gd0.5}PO4, and GdPO4.  Samples were dialyzed and 
collected in a liquid scintillation vial and dried over low heat (50oC).  The mass of the 
resulting solid was measured, then ground into a fine powder with a mortar and pestle.  
The powder was mixed with silicon standard 640c from the National Institute of 
Standards and Technology and ethanol.  Five drops of this mixture was deposited on a 
zero diffraction silicon plate and allowed to evaporate.  Each sample was scanned for 
one hour from 2θ values of 15 to 60 degrees.  Detailed scan parameters are found in 
Appendix 2. 
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3.2.11 MRI Relaxivity Measurements 
 MRI relaxivity measurements were performed by Dr. Lixin Ma.  Nanoparticles 
were centrifuged and redispersed in 18 MΩ water at a concentration of 1 mg/mL.  This 
concentration corresponds to a Gd concentration of 0.424 mg/mL (2.70 mM).  Relaxivity 
values were measured in a field strength of 7 T at room temperature.  Calculations were 
done assuming these concentrations and mean particle diameter of 26 nm (determined 
by TEM). 
 
3.3 Nanoparticle Characterization Results and Discussion 
 {LaxGd1-x}PO4 nanoparticle cores of four different compositions were successfully 
synthesized.  Each exhibits a size of 3-4 nm as confirmed by TEM.  Figure 3.3.1 shows a 
characteristic collection of nanoparticles.   
 Rietveld refinement of XRD patterns indicated that LaPO4 nanoparticles 
exhibited the rhabdophane phase consistent with the description of Buissette et al.93  
However, the compositions {La0.5Gd0.5}PO4, {La0.25Gd0.75}PO4, and GdPO4 exhibit the 
anhydrous monazite crystal phase.94  Nanoparticles consisting of LaPO4 but synthesized 
in organic media also exhibit the monazite phase.48  XRD measurements indicate 
nanoparticle grain sizes of 4.04 nm for LaPO4, 2.79 nm for {La0.5Gd0.5}PO4, 2.91 nm for 
{La0.25Gd0.75}PO4 and 3.11 nm for GdPO4.  These patterns, along with the accompanying 
Rietveld refinement, are shown in Figures 3.3.2 A-D.  Pure LaPO4 and pure GdPO4 
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exhibited larger grain sizes than their mixed lanthanide counterparts.  While the La3+ 
and Gd3+ ions are similar enough to co-crystallize, the co-crystallization process is 
retarded relative to the single element crystal.   
 
Figure 3.3.1: {LaxGd1-x}PO4 nanoparticle cores exhibit sizes of ~3-4 nm 
Size measurements of the nanoparticles using TEM match the XRD grain size 
values, indicating that the core particles consist of a single crystalline phase.  NAA of 
{La0.5Gd0.5}PO4 core nanoparticles after magnetic separation indicates a La to Gd molar 
ratio of 1.11 ± 0.03.  NAA indicates the same ratio in the {La0.25Gd0.75}PO4 system is 0.33 
± 0.02. 
Layering {La0.5Gd0.5}PO4 with GdPO4 occurs with a chemical yield of 99%.  This 
yield, combined with a core Gd:La ratio of 0.90, results in a theoretical Gd:La for the 
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{La0.5Gd0.5}PO4@4 GdPO4 shell nanoparticle of 7.91.  The experimental ratio as 
measured by NAA is 7.5 ± 0.9.  Nanoparticle growth after each shell addition was 
monitored by TEM and is shown in table 3.3.1.  These {La0.5Gd0.5}PO4@4 GdPO4 shell 
nanoparticles have a mean diameter of 22 ± 8 nm.  After one day of leaching in 18 M 
water, 99.96 ± 0.06 of the tracer activity in the Gd shell remained attached to the core 
nanoparticle.   
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Figure 3.3.2 A-D: XRD patterns and Rietveld refinement for GdPO4 (A), {La0.5Gd0.5}PO4 
(B), LaPO4 (C), and {La0.25Gd0.75}PO4 (D).  Red lines indicate the calculated spectra while 
the blue line represents the experimentally measured data. 
A B
 A  
D C 
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Table 3.3.1: Nanoparticle growth of {La0.5Gd0.5}PO4@4 GdPO4 shell@Au  
Particle System 
Diameter 
(nm) 
{La0.5Gd0.5}PO4 Core 5.0 ± 1.5 
{La0.5Gd0.5}PO4@1 shell GdPO4 7.8 ± 2.8 
{La0.5Gd0.5}PO4@2 shells GdPO4 9.9 ± 2.6 
{La0.5Gd0.5}PO4@3 shells GdPO4 13.3 ± 1.8 
{La0.5Gd0.5}PO4@4 shells GdPO4 22.4 ± 7.7 
{La0.5Gd0.5}PO4@4 shells GdPO4@Au 26.8 ± 4.9 
 
Radiotracer experiments indicate that LaPO4 shells add with a 91% chemical 
yield.  Utilizing this layering yield and a core composition with La:Gd ratio of 0.33, the 
expected La:Gd ratio of a {La0.25Gd0.75}PO4@4 LaPO4 nanoparticle is 5.17.  Experimental 
measurements with NAA indicate that the actual nanoparticle has a La:Gd ratio of 5.1 ± 
0.7.  TEM indicates that the {La0.25Gd0.75}PO4@4 LaPO4 nanoparticle has a mean 
diameter of 19.9 ± 6.5 nm.  Leaching studies in 18 M water indicate that 99.94 ± 0.13 
% of the La tracer in the shell remains attached after one day.  Overnight magnetic 
separation occurs with a 89% yield. 
Each shell addition process utilizes identical amounts of Ln and TPP.  An epitaxial 
growth mechanism with this reaction scheme would generate successively thinner shells 
of equal volume.  Thus, each successive shell would generate a smaller change in 
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diameter of the nanoparticle.  However, this phenomenon is not observed (Table 3.3.1).  
Given these observations, the nanoparticles likely grow through a process of oriented 
alignment and attachment as recently described by Li et al.95  In this process, 
nanoparticle growth occurs when smaller nanocrystals combine in a controlled fashion.  
Dilute starting material, which is insufficient to create new nanoparticles in solution, will 
fill in around the attachment point to maintain spherical nanoparticles.  The added 
lanthanide ions and the orthophosphate produced by thermolysis of Na-TPP thus 
incorporate into the crystal structure.  While the GdPO4 and LaPO4 layers possess 
slightly different crystal systems, they both generate near quantitative layer deposition 
onto the mixed {La0.5Gd0.5}PO4 or {La0.25Gd0.75}PO4 cores. 
Gold shells add easily to all compositions of the nanoparticles.  EELS-TEM of gold 
gives a clear picture of the size of the added shell.  A characteristic image is shown 
below in Figure 3.3.3.  Ratios of Au:Ln in the particles based off of a 0.5 nm gold shell on 
top of a 22.4 nm LnPO4 nanoparticle (Figure 3.3.3) predict a Au:Ln ratio of 0.65.  NAA 
measures a ratio in the particles of 0.61 ± 0.01.  Nanoparticles consisting of 
{La0.5Gd0.5}PO4@4 GdPO4
 shell@Au-PEG remain stable against aggregation in all 
biological mimic solutions tested (water, PBS, BSA) over the course of a month. 
Addition of a gold shell onto the surface also raises the possibility of 
simultaneously creating pure gold nanoparticles.  Pure gold nanoparticles would possess 
identical surface chemistry (including properties such as plasmon resonance, Figure 
3.3.4) and similar size/mass to the layered construct, making them difficult to separate.  
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The gadolinium in the layered structure allows for magnetic separation of the layered 
construct from any pure gold nanoparticles formed in the reaction.  Without separation, 
pure gold nanoparticles would effectively lower the specific activity of the construct.  
Targeting agents on the pure gold nanoparticles would compete with therapeutic 
layered nanoparticles for the limited number of receptor sites in vivo, lowering the 
targeting efficacy of the layered nanoparticles and decreasing the delivered therapeutic 
dose.   
 
Figure 3.3.3: EELS-TEM of a characteristic {La0.5Gd0.5}PO4@4 GdPO4
 shell@Au 
nanoparticle showing the width of the gold surface layer 
While lanthanum and gadolinium are both present in the nanoparticle solution, 
this does not confirm that they are co-crystallized.  There could be separate LaPO4 and 
GdPO4 nanoparticles without mixture of lanthanides.  This possibility was discounted by 
0.5 nm Au shell 
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two experiments.  First, NAA confirms that magnetically separating the nanoparticles 
does not enrich the nanoparticles in Gd content.  Nanoparticles that contain only LaPO4 
will not be attracted to the magnet.  However, La:Gd ratios remain constant after 
separation.  Next, EELS-TEM confirms the presence of all three elements, lanthanum, 
gadolinium, and gold, in a cluster of particles.  Those images are shown in Figure 3.3.5. 
 
Figure 3.3.4: UV-Vis of {La0.5Gd0.5}PO4@4 GdPO4 shell@Au nanoparticles.  Absorbance 
peak occurs at 523 nm 
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Figure 3.3.5: EELS-TEM confirms the presence of lanthanum, gadolinium, and gold in 
each nanoparticle.  The top left image shows the standard TEM of the same particles. 
The synthesis of the gold coated, four LnPO4 shell system has an overall 
radiochemical yield of 57.5%.  Correcting this value for the decay of 225Ac, the overall 
chemical yield for incorporation of 225Ac in the nanoparticles is ~76% at the end of the 4 
day synthesis.  Figure 3.3.6 shows a schematic of a completed {LaxGd1-x}PO4@4 
LnPO4@Au nanoparticle.   
GdPO4 nanoparticles are currently being investigated as potential MRI contrast 
agents due to the paramagnetic properties of gadolinium.96  The Gd3+ ion will possess 7 
unpaired electrons, the highest number possible using commonly accessible orbitals.  
MRI measurements of the GdPO4 shell system indicate r1 values of 1.00 ± 0.01 s
-1 mM-1 
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and r2 values of 44.0 ± 4.2 s
-1 mM-1.  The r2 value of these nanoparticles falls on the 
lower end of approved contrast agents.  MRI contrast requires interaction between the 
gadolinium and the water medium.  We hypothesize that the gold shell in the 
nanoparticles partially inhibits the action of the large quantity of gadolinium in the 
nanoparticle.  MRI contrast remains a compelling application for the GdPO4 shell 
nanoparticles when combined with their therapeutic and potential SPECT capabilities.  
While unlikely to win approval as a standalone contrast agent, the MRI properties of the 
{La0.5Gd0.5}PO4@4 GdPO4 shell@Au system warrant further study.  The collection 
efficiency with overnight magnetic separation of {La0.5Gd0.5}PO4@4 GdPO4 shell@Au 
nanoparticles is typically on the order of ~90%. 
 
Figure 3.3.6: Idealized schematic of a {LaxGd1-x}PO4@4 LnPO4@Au nanoparticle.  The 
decay of 225Ac and subsequent retention of the 221Fr daughter product are illustrated. 
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 Retention of 225Ac in the nanoparticle depends on the core composition and the 
number/type of shells added.  {La0.5Gd0.5}PO4 core nanoparticles without additional 
shells retain 99.04% ± 0.07% of 225Ac throughout the three week observation period. 
Adding two shells of {La0.5Gd0.5}PO4 to this core increases 
225Ac retention to 99.42 ± 
0.02%.  Systems with four shells retain 225Ac to an even higher degree.  The 
{La0.25Gd0.75}PO4@4 LaPO4 shell@Au system sequesters 99.97 ± 0.01% of the 
225Ac while 
the {La0.5Gd0.5}PO4@4 GdPO4 shells@Au system retains 99.996 ± 0.002%.   
 Nanoparticles where La comprises a portion of the core retain a higher 
proportion of 225Ac than compositions that include only Gd.  The increased retention 
likely results from isomorphism between 225Ac3+ and La3+ ions.  For 8-coordinate 
configurations, the 225Ac3+ has an ionic radius of 1.36 Å compared with 1.30 Å for La3+ 
and 1.19 Å for Gd3+.97   Further, 225Ac retention in the {La0.5Gd0.5}PO4@4 GdPO4 shell@Au 
system improves by an order of magnitude over the corresponding 4 LaPO4 shell system.  
This difference results from the larger layering yield observed in the GdPO4 shell 
addition (larger particles with thicker shells).  The 225Ac must diffuse through a longer 
path to escape the GdPO4 shells than the LaPO4 system.  Due to the lower overall 
gadolinium content in the lanthanum shell system, the ratio of Gd:La used in the core of 
the LaPO4 shell particles was increased from 1:1 to 3:1 so that the nanoparticles could 
be magnetically separated following gold shell addition.  Though this new 
{Gd0.75La0.25}PO4 core still contains the 
225Ac to a high degree, retention was measured 
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to be slightly lower than the value obtained with the {Gd0.5La0.5}PO4 core. A summary of 
the 225Ac and 221Fr retention values are given in Table 3.3.2. 
Table 3.3.2: Retention of 225Ac and its daughter 221Fr in different nanoparticle constructs 
Core Shell Material # of Shells 225Ac retentiona 221Fr retentionb 
{La0.5Gd0.5}PO4 None 0 99.16 ± 0.02% 60.2% ± 3.0% 
{La0.5Gd0.5}PO4 {La0.5Gd0.5}PO4 2 99.42 ± 0.02% 69.2 ± 1.7% 
{La0.25Gd0.75}PO4 LaPO4 4 99.96 ± 0.01% 79.4 ± 1.6% 
{La0.25Gd0.75}PO4 GdPO4 4 99.98 ± 0.02% 90.9 ± 0.9% 
{La0.5Gd0.5}PO4 LaPO4 4 99.97 ± 0.01% 79.9 ± 1.9% 
{La0.5Gd0.5}PO4 GdPO4 4 99.996 ± 0.002% 89.3 ± 1.8% 
a 225Ac retention after 3 weeks   b 221Fr retention after 3 weeks 
 Measurements of 221Fr retention indicate that the sequestration efficiency also 
depends on the number and composition of shells added to the nanoparticle.  Unlike 
225Ac, retention of 221Fr also depends to some degree on the time since synthesis.  The 
amount of 221Fr retention typically drops slightly over the course of the first week of 
observation, then stabilizes during the second and third week.  After three weeks, the 
{Gd0.5La0.5}(
225Ac)PO4 core contains 60.2% ± 3.0% of the 
221Fr daughter.  Retention 
increases to 69.2 ± 1.7% after adding two shells of {Gd0.5La0.5}PO4.  Four shells of LnPO4 
further increases 221Fr retention values.  The {La0.25Gd0.75}PO4@4LaPO4@Au system 
initially retains 89.8 ± 0.5% of the 221Fr.  This retention decreases over the course of the 
first week and stabilizes at 79.9 ± 1.9%.  The {La0.5Gd0.5}PO4@4GdPO4@Au system 
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initially retains 97.8 ± 0.5% of the 221Fr daughter.  This retention value also decreases 
over the course of a week, stabilizing at 89.3 ± 1.8%.  Francium-221 retention data is 
presented in Figure 3.3.7.  For comparison purposes, previously reported La(225Ac)PO4 
nanoparticles synthesized in organic solvents retain only ~50% of the 221Fr daughter.48   
 
Figure 3.3.7: 221Fr retention data for the {La0.5Gd0.5}PO4@4 GdPO4 shell@Au and 
{La0.25Gd0.75}PO4@4 LaPO4 shell@Au nanoparticle systems 
 Though the layering efficiencies of both the LaPO4 and GdPO4 systems are > 90%, 
GdPO4 shells clearly contain the 
221Fr daughter to a higher degree than their LaPO4 shell 
counterparts in vitro.  Part of this improved retention can be attributed to the higher 
chemical layering yield of GdPO4.  Nanoparticles with GdPO4 shells are slightly larger and 
have more marginally more material that the recoiling daughter must pass through to 
escape.  Additionally, the higher electron density of the GdPO4 creates a slightly higher 
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stopping power.  While daughter products are retained in the nanoparticle, the 
associated α-particles lose a negligible fraction of their energy in traversing the 
nanoparticle.  A 6 MeV α-particle loses less than 0.2% of its energy in the layered 
nanoparticle whereas the range of the 100 keV recoiling daughters is ~20 nm in bulk 
LnPO4.
50  Moreover, a portion of the kinetic energy of the daughter particle may be 
transferred to the entire particle.  If a portion of the recoil energy is distributed 
throughout the highly structured crystalline lattice, the recoiling range of the daughter 
radionuclides will be significantly decreased.98  To some extent, the nanoparticle may be 
able to recoil as a unit in solution, absorbing some of the daughter recoil energy and 
retarding the daughter radionuclide’s motion out of the center of the nanoparticle.  
Again, the more massive GdPO4 shell system would absorb slightly more recoil energy 
than the lighter LaPO4 shell system. 
 
3.4 Biological Targeting Experimental 
3.4.1 Materials and Measurements 
 All animal experiments were performed according to either the protocols set 
forth by the University of Missouri-Columbia Institutional Animal Care and Use 
Committee approved protocol number 7055 or according to the Institutional Animal 
Care and Use Committee of the University of Tennessee approved protocol 1502.  
Chemicals were used as received from Sigma Aldrich unless otherwise noted.  Anti-
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synaptophysin and anti-glial fibrillary acidic protein (GFAP) antibodies were received 
from Dako.  MAb 201b and EMT-6 tumor cells were provided by Dr. Stephen Kennel.  
Lipoamide-dPEG12-COOH was received from Quanta Biodesign.  Sections 3.4.5 - 3.4.8 
and 3.4.10 were performed by Dr. Stephen Kennel and Dr. Jonathan Wall at the 
University of Tennessee - Knoxville Graduate School of Medicine.   
3.4.2 Surface Functionalization 
Nanoparticles (12 mg in 10 mL water) were functionalized using a water soluble 
lipoamide-dPEG12-COOH linker.  The structure of the linker is shown in Figure 3.4.1.  Two 
mg of dPEG were added to a solution of 12 mg of {LaxGd1-x}PO4@4 LnPO4 shell@Au 
nanoparticles in 5 mL of PBS, followed by 6 mg of tris(2-carboxyethyl)phosphine (TCEP) 
reducing agent to cleave the disulfide bond and facilitate citrate displacement. The 
solution pH was adjusted to 7 with 0.1 M NaOH monitored by pH test strips and the 
reaction mixture was stirred for 4 hours.  Nanoparticles were centrifuged at 3000 g for 3 
minutes and the supernatant containing excess dPEG decanted via pipette.  Connection 
of the linker was confirmed by a shift in the plasmon resonance near 540 nm as 
monitored by UV-Vis spectroscopy before and after the addition of the linker.  The 
surface plasmon resonance is highly sensitive to changes in the dielectric constant at the 
gold surface.  A shift in the plasmon resonance indicates a change in the surface 
environment of the nanoparticle and is indicative of antibody attachment. 
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Figure 3.4.1: Structure of lipoamide-dPEG12-COOH linker 
3.4.3 Antibody Conjugation 
 Five separate antibodies (anti-synaptophysin, anti-GFAP, mAb 201b, HuM-195, 
and panitumumab) were individually conjugated to the nanoparticles using the same 
basic procedure.  Each antibody is an immunoglobin G type with a molecular mass of 
~150 kDa.  In a standard conjugation, 0.5 mg of dPEG modified  
{LaxGd1-x}PO4@4 LnPO4@Au nanoparticles was dispersed in 0.5 mL of PBS in a 1 mL 
microcentrifuge vial.  To this vial, 8 µL of 10 mg/mL sulfo-NHS and 80 µL of 10 mg/mL 
EDC were added and stirred for 30 minutes.  The solution was centrifuged for 3 minutes 
at 3000 g and the supernatant decanted via pipette to remove excess EDC/sulfo-NHS.  
The nanoparticles were redispersed in 0.5 mL of PBS and stirred with 0.5 mg of antibody 
overnight (pH = 7.4).  The reaction was quenched with glycine and stirred for 15 
minutes.  Particles were again centrifuged as above and redispersed in 0.5 mL of PBS 
containing 5 mg/mL BSA.  The mechanism for the amide reaction is shown in Figure 
3.4.2. 
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Figure 3.4.2: Amide bond formation by carbodiimide activation 
3.4.4 In Vitro Antibody Quantification and Competition Assay 
 Panitumumab was added to the nanoparticles as in 3.4.3.  Nanoparticles were 
centrifuged and washed with PBS 5 times before determining surface protein 
concentration via a modified Lowry assay.99  Briefly, eleven standards were created with 
varying amounts of BSA (0-20 μg) for comparison purposes.  Each polypropylene tube 
was filled with the appropriate amount of BSA, 10 μL of PBS buffer, and diluted to 300 
μL with DI water.  Samples were created by taking 6, 8, or 10 μL of nanoparticle solution, 
adding PBS to bring the volume to 10 μL, then diluting to a volume of 300 μL with 
deionized water.  Solution A was prepared by mixing 0.5 mL of 1% cupric sulfate and 0.5 
mL of 2% potassium tartrate with a solution of 50 mL of 2% sodium carbonate/0.1 M 
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NaOH.  Solution A (1.5 mL) was added to each tube, vortexed, and allowed to stand at 
room temperature for 10 minutes.  Next, 150 μL of 1 M phenol was added to each tube 
and immediately vortexed.  The tubes were allowed to stand at room temperature for 
30 minutes before measuring their absorbance at 750 nm.  Absorbance in the 
nanoparticle samples was compared to the absorbance of the BSA standard to 
determine protein concentration on the nanoparticles.  Nanoparticles with PEG 
attached were treated similarly and used as controls for the antibody labeled 
nanoparticle samples.  Absorbance from the PEG coated nanoparticles was subtracted 
from the absorbance of the antibody labeled nanoparticles.  The number of antibodies 
per nanoparticle was calculated by assuming a 150 kDa antibody and a nanoparticle 
consisting of a 22.4 nm diameter LnPO4 with a density of 5 g/cm
3 and a 0.5 nm thick 
outer layer of gold of density of 19.3 g/cm3.  An example calculation is given in Appendix 
3. 
 Human epidermal growth factor receptor (hEGFR) was coated onto well plates 
(50 ng hEGFR/50 μL DPBS per well) and incubated overnight at 4oC.  The following day, 
hEGFR was removed and each well washed with 100 μL of 1% BSA in PBS.  The wells 
were kept at room temperature for 1 hour before removal of PBS.  A series of 11 
dilutions of HuM-195, panitumumab, nanoparticle-HuM-195 conjugates, and 
nanoparticle-panitumumab conjugates with protein concentrations from 0.8 ng/mL – 40 
μg/mL (as determined by Lowry assay) was prepared.  Twenty-five μL of each dilution 
and a control consisting of PBS was added to the wells in triplicate followed by addition 
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of 25 μL of panitumumab antibody labeled with 50,000 cpm 131I.  The wells were 
incubated for 4 hours at 37oC, then washed 3x with 150 μL of 1% BSA in PBS.  One 
hundred μL of 0.2 M NaOH was added to each well to release the bound hEGFR.  Wells 
were shaken for 2 minutes at a moderate speed and their contents absorbed onto filters 
and transferred into polypropylene tubes for counting.  The amount of radioactivity 
absorbed onto the filters was then used to compare the binding activity of the 
nanoparticle-antibody conjugates to that of the free antibodies.   
 
3.4.5 Radiotracer Antibody Saturation Studies and Biodistribution 
 MAb 201b was radioiodinated with 125I by the chloramine T method. 100  Briefly, 
15 μg of antibody  was added to 75 μL of a freshly prepared solution of 50 mM NaPO4.  
Na125I (6 μL, 3 mCi) was added to this solution followed by 75 μL of 4 mg/mL 
chloramines T in 50 mM NaPO4.  The solution was mixed with a  stir bar for 30 seconds, 
then quenched by addition of 300 μL of 12.6 mM sodium metabisulfate in 50 mM 
NaPO4.  The quenched reaction was dialyzed 2 times versus PBS to remove unbound 
125I.  
Three 500 μL microcentrifuge tubes were set up containing 5, 55, or 250 μg of mAb 
201b.  Each mAb addition contained 5 μg of radiolabeled antibody and an appropriate 
amount of cold antibody to provide the correct total mAb mass in a final volume of 100 
μL in PBS.  Ten μL of 0.5 M sodium phosphate buffer, pH 7.6 was added to each tube.  
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Nanoparticles (1.5 mg in 600 μL of PBS) were activated as described in 3.4.3. Two 
hundred μL of this solution was dispensed into each of 3 tubes containing antibody. 
 The mixture was allowed to react overnight, then quenched by addition of 5 μL 
of 1 M glycine and stirred for 1 hour.  The particles were centrifuged as above and the 
supernatant sampled for 125I content.  The number of antibodies per nanoparticle was 
quantified by calculating the average mass of an individual particle assuming an inner 
LnPO4 shell with a 22.4 nm diameter and a density of 5 g/cm
3 and a 0.5 nm thick outer 
layer of gold with a density of 19.3 g/cm3.   
 Nanoparticles were centrifuged again, resuspended in 0.5 mL of 5 mg/mL BSA in 
PBS and sonicated (Branson microprobe) for 2-5 sec to complete dispersal.  Another 0.5 
mL of BSA/PBS buffer was added to each preparation and 200 μL of the three 
preparations injected via the tail vein into 4 female BALB/c mice (body mass ∼20 g) per 
group for a total of 12 mice.  Mice (2 per group) were sacrificed at 1 hr or 24 hrs post-
injection and liver, spleen, kidneys and lung were harvested for biodistribution studies.  
Each organ was counted for 125I, 221Fr, and 213Bi content at ~20 minutes post sacrifice 
and then again after 213Bi equilibrium had been established 3 hrs post-sacrifice.   
3.4.6 Biodistribution and in vivo Retention Studies with {La0.5Gd0.5}PO4@4GdPO4@Au-
PEG-mAb 201b 
 Biodistribution and 225Ac daughter retention assays were done on three separate 
groups consisting of six female BALB/c mice per group, injected I.V. (tail vein).  Groups 1 
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and 2 were injected with {La0.5Gd0.5}PO4@4GdPO4@Au-PEG-mAb 201b, while group 3 
was treated with {La0.5Gd0.5}PO4@4GdPO4@Au-PEG nanoparticles as a control. Group 1 
mice received 14.6 μg of conjugates with 74 kBq of Ac-225 and ~ 5 μg of attached mAb 
201b (as measured in 3.4.5) in 100 µL of PBS.  Group 2 received an identical amount of 
targeted nanoparticles but with co-injection of 750 µg of unconjugated mAb 201b as 
competitor.  Group 3 received the same amount of nanoparticles and 225Ac, but with no 
conjugated antibody.  Mice received food and water ad libitum in a light/dark cycle 
environment.  Three mice from each injection group were sacrificed at time points of 1 
and 24 hours post-injection for biodistribution and in vivo retention studies.  Mouse 
lung, liver, spleen, and kidneys were harvested to evaluate the amount of both 221Fr and 
213Bi in target organs.  Each organ was massed and counted for content of 221Fr and 213Bi 
in a γ scintillation counter at a specific time post sacrifice and again after the 
radioisotopes had achieved decay equilibrium (>3 h). Quantities of 221Fr and 213Bi 
present at the time of animal sacrifice were determined by appropriate decay 
corrections as previously described.48 
3.4.7 MicroSPECT/CT Imaging:  
 Small animal imaging was performed using a Siemens Preclinical Imaging 
microCAT IIþ SPECT dual modality platform on loan to the University of Tennessee.  
Mice were injected I.V. with approximately 3 MBq of 225Ac in the same three groups and 
with the same volumes as in 3.4.6.  Instead of the large excess described in 3.4.6, an 
identical quantity of free antibody was injected in group 2, thus the mice in the 
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competition group had a different ratio of cold competitor to nanoparticle conjugate 
and competition was not as complete.  Animals were sacrificed by overdose of 
isoflurane at 1 hour post injection and imaged via microSPECT/CT 3 hours post-sacrifice 
when the 225Ac and its daughters had reached equilibrium. SPECT data for the final 
images were acquired as previously described.48 
3.4.8 Effect of Clodronate Liposomes on Biodistribution and Uptake 
 Biodistribution and daughter retention assays were done using I.V. injections in 
four groups of mice, consisting of six mice per group.  Mice received 14.6 μg of 
{La0.5Gd0.5}PO4@4GdPO4@Au-PEG-mAb 201b nanoparticle conjugates with 74 kBq of 
225Ac and ~ 5 μg of attached mAb 201b in 100 µL of PBS.  Group 1 was injected with 
clodronate liposomes followed by nanoparticle-mAb 201b conjugates.  Mice in group 2 
were injected with clodronate liposomes followed by a mixture of 500 μg of 
unconjugated mAb 201b and nanoparticle-mAb 201b conjugates. Group 3 and 4 mice 
were injected as group 1 and 2, respectively, except that they were not pretreated with 
clodronate liposomes.  Mice were housed with food and water ad libitum in a light/dark 
cycle environment.  Three mice from each injection group were sacrificed at 1 and 24 
hours post injection for biodistribution and in vivo retention studies.  A γ scintillation 
counter windowed for 212 keV (221Fr) and 440 keV (213Bi) was used to evaluate the 
amount of radioactivity present in the harvested lungs, liver, spleen, and kidneys. 
Quantities of 221Fr and 213Bi present at the precise time of animal sacrifice were 
determined by appropriate crossover and decay corrections as previously described.48  
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3.4.9 Electron Microscopy Samples 
 Mice were anesthetized with an oxygen/isoflurane mixture.  Each mouse 
received 100 μL of {La0.5Gd0.5}PO4@4GdPO4@Au-PEG-mAb 201b non-radioactive 
conjugates prepared as described in 3.4.3.  After 45 minutes, each mouse was sacrificed 
by injection of 4 mL of fixative buffer solution (2% paraformaldehyde, 2% 
glutaraldehyde, 0.1M cacodylate, hereafter referred to as simply cacodylate) via the 
catheter as below and euthanized via cervical dislocation.  Mouse tissues were 
embedded in resin, sliced, and fixed for examination on Cu TEM grids (Ted Pella).  
Electron microscopy studies were performed at the University of Missouri Electron 
Microscopy Core on a JEOL 1400 instrument. 
3.4.10 EMT-6 Therapy Study 
 Fifteen mice were injected I.V. (tail vein) with clodronate liposomes followed the 
next day by injection of 80,000 log phase EMT-6 cells in 0.2 mL of PBS.  EMT-6 cells form 
tumor colonies in lung tissue simulating metastatic disease.101  Forty-eight hours after 
tumor cell injection, 5 mice were injected with 100 µL of PBS, 5 mice with free mAb 
201b mixed with ~37 kBq of {La0.5Gd0.5}PO4@4GdPO4@Au-PEG-mAb 201b conjugates, 
and 5 mice with ~37 kBq of nanoparticle-mAb 201B conjugates.  Mice were sacrificed at 
7 days post EMT-6 cell injection.  Lungs were inflated via tracheal catheter with Bouin’s 
fixative (0.2% picric acid, 2% paraformaldehyde, 40% formalin in water), suspended in 
fixative for 24 hours and then washed into 70% ethanol/PBS.  Paraffin sections were cut, 
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stained, and counted by a blinded observer to quantitate tumor colony growth.  
Statistical significance was calculated at the 95% confidence level using a two tailed 
Student’s T test with unequal variance.  Separate samples were fixed in cacodylate 
buffer and allowed to decay for 6 months before examination on electron microscopy.   
3.4.11 In Vivo Evaluation of Blood Brain Barrier Penetration with Anti-GFAP and Anti-
Synaptophysin 
 Anti-GFAP and anti-synaptophysin antibodies were added to 
{La0.5Gd0.5}PO4@4GdPO4@Au-PEG nanoparticles as described in 3.4.3.  The attachment 
of the antibodies to the nanoparticles was confirmed with immunohistochemistry.  The 
anti-synaptophysin and anti-GFAP antibody labeled nanoparticles were incubated with 
normal brain and used as a primary immunochemistry label to target these proteins in 
normal brain.  Secondary antibody biotin and avidin-horseradish peroxidase were used 
to detect the presence of primary antibody.  Diaminobenzadine (DAB) was used as the 
color agent. 
 Mice were anesthetized with an isoflurane (1.5%) and oxygen mixture and 
catheterized via partial dissection in either the femoral or axillary vein using a 0.115 mm 
outer diameter, 0.10 mm inner diameter catheter (A.P. Extrusion, Salem, N.H.).  
Mannitol (50 µL) was injected to open the blood-brain barrier.  One hundred µL (300 µg) 
of immunolabeled nanoparticles (anti-synaptophysin or anti-GFAP) were injected 
intravenously into each mouse.  Under terminal anesthesia, mice were sacrificed by 
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perfusion cacodylate buffer 30 minutes post-injection.  Death was ensured via cervical 
dislocation.  The brain, tongue, colon, muscle, heart, spleen, kidney, lung, and liver were 
harvested. The tissue was prepared for analysis by TEM, light microscopy, and NAA.   
 
3.5 Biological Targeting Results and Discussion 
3.5.1 Characterization of Antibody Attachment 
 The absorption wavelength of the plasmon resonance as measured by UV-Vis 
spectroscopy steadily increases as larger groups are added to the nanoparticle surface.  
Citrate coated {La0.5Gd0.5}PO4@4GdPO4@Au nanoparticles absorb maximally at 523 nm.  
After addition of the lipoamide-dPEG12-COOH linker, this absorption peak red-shifts to 
529 nm.  After antibody addition, the plasmon peak further red-shifts to 537 nm.  The 
changes in plasmon resonance for the addition of the anti-synaptophysin antibody are 
shown in Figure 3.5.1. 
 The antibody addition process also causes a drastic increase in the hydrodynamic 
diameter of the nanoparticles.  From an initial hydrodynamic diameter of 101.4 ± 1.5 
nm, addition of mAb 201b causes it to grow to 1498 ± 77 nm.  Zeta potential also 
becomes more positive as a result of mAb 201b addition.  The nanoparticle surface has 
been passivated by the addition of PEG and mAb, so that the nanoparticles will not 
aggregate despite the more neutral zeta potential. 
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Figure 3.5.1: UV-Vis spectra showing the red-shift in the plasmon resonance as PEG and 
antibody are added to citrate coated {La0.5Gd0.5}PO4@4GdPO4@Au nanoparticles.  
Table 3.5.1: Hydrodynamic diameter and zeta potential of {La0.5Gd0.5}PO4@GdPO4@Au-
mAb-201b nanoparticles. 
Nanoparticle composition Hydrodynamic 
diameter (nm) 
Zeta potential 
(mV) 
{La0.5Gd0.5}PO4@GdPO4@Au-citrate 101.4 ± 1.5 -63.2 ± 1.6 
{La0.5Gd0.5}PO4@GdPO4@Au-PEG 382.3 ± 6.5 -56.4 ± 0.1 
{La0.5Gd0.5}PO4@GdPO4@Au-mAb-201b 1498 ± 77 -27.9 ± 2.4 
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 The Lowry assay detected 0.22 mg of HuM-195 and 0.19 mg of panitumumab 
bound to the nanoparticles.  This quantity compares with 0.875 mg of each antibody 
which was used in the synthesis, giving a labeling yield of 25.1% for HuM-195 and 21.7% 
for panitumumab.  These labeling yields correspond to an average of 4.9 HuM-195 
antibodies per nanoparticle and an average of 4.3 panitumumab antibodies per 
nanoparticle.   
 Nanoparticle-panitumumab conjugates show binding characteristics similar to 
the panitumumab antibody.  However, the binding affinity of the conjugates, as 
measured by the IC50 value, appears to be roughly 4.5x lower than the free antibody.  
This difference is likely explained by the loading of multiple antibodies onto the 
nanoparticle.  Binding to hEGFR will only occur through one of the average 4.3 
antibodies on the nanoparticle surface.  The other antibodies remain, but do not take up 
receptor sites, hence the apparent decrease in binding affinity.  Correcting for this factor 
brings the binding affinity of the nanoparticle-panitumumab conjugate in line with the 
free panitumumab antibody.  The conjugation process therefore does not decrease the 
inherent binding ability of the antibody.  HuM-195 and nanoparticle-Hum 195 conjugate 
controls show no affinity for the hEGFR receptor at any concentration.  Results from the 
competition assay are shown in Figure 3.5.2. 
 Antibody conjugation was also quantified using a 125I radiotracer to label mAb 
201b prior to attachment.  MAb 201b has high affinity and specificity for 
thrombomodulin in vivo, which is expressed primarily in lung tissue.  Actinium-225 was 
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recovered nearly quantitatively in these antibody saturation experiments, indicating 
little loss of nanoparticles.  Attachment of mAb 201b varied with amount added 
according to table 3.5.2.  The amount of antibody bound approaches a maximum, 
indicating saturation of the available sites at slightly over 4 antibodies per nanoparticle.  
The maximum antibody bound per particle corresponds well with the labeling yield seen 
with panitumumab and HuM-195.   
 
Figure 3.5.2: Nanoparticle-panitumumab conjugates show a decreased binding affinity 
relative to free antibody due to the binding of multiple panitumumab molecules onto a 
single nanoparticle.  Nanoparticle-Hum 195 conjugates and free Hum 195 antibody 
show no affinity for the hEGFR receptor used at any concentration. 
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Table 3.5.2: Labeling efficiency of mAb 201b onto 0.5 mg of {La0.5Gd0.5}(
225Ac)PO4@4 
GdPO4 shell@Au nanoparticles 
mAb added (μg) mAb bound (μg) % bound mAb/NP 
5 4.5 90 0.65 
55 26.0 48 3.39 
255 32.2 13 4.20 
 
3.5.2 Lung Targeting with mAb 201b 
 Localization of activity in the lung at 1 hour depends on the amount of antibody 
used in the preparation.  Nanoparticles with a larger amount of antibody bound show 
higher uptake by lung tissue.  This effect remains evident after 24 hours, as shown in 
Figure 3.5.3.  
 The %ID of each radionuclide detected in lung tissue does not match.  This 
indicates that the 125I and 225Ac daughter products are becoming separated in vivo.  
Further, the ratio of %ID 225Ac to %ID 125I detected in depends both on the amount of 
antibody loaded onto the individual particles and the time since injection.  Over a 24 
hour period, the ratio increases by roughly a factor of 5.  Those ratios are shown in 
Table 3.5.3. 
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Figure 3.5.3: Saturating the nanoparticle with antibody increases targeting and 
retention in lung tissue at time points of 1 hour and 24 hours.  Percent ID/g increases as 
a function of the amount of antibody used in the synthesis at both time points.  
 
Table 3.5.3: Ratio of %ID/g 225Ac to %ID/g 125I in lung tissue at 1 hour and 24 hours 
antibody added (μg) 1 h 24 h 
5 0.15 1.50 
55 0.97 5.45 
250 1.08 4.47 
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 There are a variety of explanations for the discrepancy between %ID 225Ac and 
%ID 125I that present a complicated picture of in vivo interactions.  When the amount of 
antibody on each particle is low, the ratio of %ID of 225Ac to %ID of 125I at one hour is 
0.15, indicating that some nanoparticle must be cleaved from antibody and leave the 
lung.  This ratio with moderate and high antibody loading onto the nanoparticles is close 
to unity at 1 hour, indicating that the radiolabeled antibody and nanoparticle are 
remaining intact.  More than one antibody may bind the nanoparticle to the lung, 
stabilizing the attachment.  This interpretation is consistent with the number of 
antibodies bound to each nanoparticle.  If more than one antibody is present per 
nanoparticle, cooperative binding ensures that the nanoparticle remains attached to the 
target site.   
 At 24 hrs, 125I is nearly gone in all samples.  225Ac is also lost, but at a drastically 
slower rate.  The loss of 125I is also much faster than loss of the free antibody.100  The 
increase of %ID 225Ac relative to %ID 125I from the 1 h to 24 h time point indicates that 
the nanoparticles are being retained in the lung tissue while either the targeting 
antibody or the 125I label separates from the nanoparticle.  Iodine-125 linked by the 
chloramines T method will cleave once inside the cellular environment and release into 
circulation.102  TEM images taken of the lung show the presence of nanoparticles in the 
lung epithelium (Figure 3.5.4), indicating that the change in ratio likely results from 
cleavage of 125I from the antibody.  Other tissues show similar changes in the %ID ratio 
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from 1 to 24 hours indicating that the change results primarily from the loss of 125I.  This 
could be confirmed by measuring the thyroid for escaped 125I. 
  
Figure 3.5.4: {Gd0.5La0.5}PO4@GdPO4@Au nanoparticles bound to the vascular side of 
lung epithelium (A), contiguous with red blood cells (B), and actively being endocytosed 
(C) into a lung epithelium vesicle (D). 
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Figure 3.5.5 A and B: Biodistribution of {Gd0.5La0.5}PO4@4 GdPO4 shell@Au-PEG-mAb 
201b nanoparticles at 1 hour post-injection (A) and 24 hours post-injection (B). 
A 
B 
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 Given the increases in lung uptake with additional amounts of antibody, 
{Gd0.5La0.5}PO4@4 GdPO4 shell@Au and {Gd0.25La0.75}PO4@4 LaPO4 shell@Au 
nanoparticles were saturated with mAb 201b for biodistribution studies by combination 
of equal masses of mAb and nanoparticles during synthesis.  Targeted nanoparticles in 
each case were compared with non-targeted, PEG coated nanoparticles and with 
receptor-blocked mice.  Biodistribution results are shown in Figure 3.5.5 A and B at time 
points of 1 and 24 hours. 
 In vivo biodistribution experiments of the {Gd0.5La0.5}(
225Ac)PO4@4 GdPO4 
shell@Au-PEG-mAb 201b nanoparticles demonstrated uptake in the lung consistent 
with the binding properties of mAb 201b.  The nanoparticles exhibit high lung uptake 
with the antibody conjugate after 1 hour (151 %ID/g). This high lung uptake of 
nanoparticles drops to 16.8 %ID/g when competed with unconjugated antibody.  Thus, 
the antibody retains its binding affinity and specificity even after conjugation to the 
nanoparticles.  Further, nanoparticle uptake in the lung is primarily through antibody-
mediated binding.   
 In vivo, 69% ± 3% of the 213Bi from the 225Ac generator was retained in lung tissue 
after 1 hour and 84% ± 3% was retained after 24 hours.  Similar 213Bi retention values 
were observed in liver (1 hour, 81% ± 4%; 24 hours, 92% ± 1%) and spleen tissue (1 hour, 
72% ± 3%; 24 hours, 82% ± 16%). In contrast to 225Ac conjugates made from metal 
chelation, a very small fraction of the injected dose travels to the kidney.  Under 5% of 
the ID/g of the nanoparticles locate in the kidney after 1 hour and less than 1% after 24 
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hours.  Renal toxicity associated with 213Bi relocation to the kidney typically forms the 
dose-limiting factor in 225Ac α-generator therapies,103 however with 
{Gd0.5La0.5}(
225Ac)PO4@4 GdPO4 shell@Au-PEG-mAb 201b nanoparticles only 2.8% of the 
213Bi from the injected dose migrated to kidney tissues after 1 hour.  After 24 hours, this 
number further decreased to 1.5%. 
 A larger dose (ca. 3.0 MBq/animal) of 225Ac NPs was imaged using CT/SPECT of 
the 221Fr γ ray (218 keV, 11.6%).  The CT/SPECT images (Figure 3.5.6) clearly show large 
uptake in the lung for the {La0.5Gd0.5}(
225Ac)PO4@GdPO4@Au-mAb-201b nanoparticles 
which is in agreement with the biodistribution data.  When competed with 
unconjugated mAb 201b antibody, the images reflect the higher RES uptake in the liver 
and spleen.  Unconjugated, PEG-coated nanoparticles also show high uptake by the RES, 
further indicating that the lung uptake is antibody-mediated and not due to particulate 
trapping in the small capillary system of the lung. 
 Compared with single α-emitting therapies, the use of in vivo α generators holds 
the potential to deliver a much larger biologically effective dose to target tissues.  The 
high, receptor-mediated uptake of nanoparticles in the lung epithelium demonstrates 
the ability of {La0.5Gd0.5}(
225Ac)PO4@GdPO4@Au nanoparticles to deliver 
225Ac to a tissue 
target in the vascular space.  The nanoparticle construct improves 225Ac daughter 
retention relative to both chelate approaches and previous nanoparticle systems both in 
vitro and in vivo.  In vivo, the increase of retention of 213Bi in the target tissue over time 
results from a combination the intrinsic retention of the nanoparticle and its  
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Figure 3.5.6: CT-SPECT scans of {La0.5Gd0.5}(
225Ac)PO4@GdPO4@Au-mAb-201b show high 
uptake in the lung when targeted (left column).  When competed with mAb-201b 
(middle column) and when untargeted (right column), uptake occurs in the RES. 
endocytosis into lung epithelium.  Daughters later in the decay series, such as 213Bi, are 
harder to retain because prior decays can move the remaining α-emitting nuclides out 
of the nanoparticle core towards the nanoparticle surface.  From this position nearer 
the surface, subsequent α decays are more likely to release the daughter nuclide from 
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the nanoparticle.  Thus, the retention values for 221Fr should be higher than those for 
213Bi.  The amount of 213Bi which relocates to the kidney from other tissues shows 
marked improvement with the {La0.5Gd0.5}(
225Ac)PO4@GdPO4@Au-mAb-201b system 
compared to core only nanoparticles.  Layered {La0.5Gd0.5}(
225Ac)PO4@4 GdPO4 shell@Au 
nanoparticles allow only 3% of 213Bi ID to migrate to the kidney after 1 hour and 1.5% 
after 24 hours.  In the core only La(225Ac)PO4 system, 10% of the 
213Bi ID relocated to the 
kidney after 1 hour and 5% after 24 hours. 
 While the  {Gd0.5La0.5}PO4@4 GdPO4 shell@Au-PEG-mAb 201b nanoparticles clear 
rapidly from the lungs into the liver and spleen, previous strategies used to reduce 
reticuloendothelial functioning such as treatment with clodronate liposomes could be 
applied to mitigate the rapid clearance.104, 105, 106  Uptake at various time points as a 
result of injecting mice with clodronate liposomes prior to injection of 
{La0.5Gd0.5}(
225Ac)PO4@4 GdPO4 shell@Au-mAb-201b or {La0.s5Gd0.75}(
225Ac)PO4@4 LaPO4 
shell@Au-mAb-201b nanoparticles is shown in Figures 3.5.7 A-D. 
 Using clodronate liposomes drastically improves target tissue uptake at each 
time point.  The liposomes selectively deplete macrophages, which are responsible for 
clearing large particulates such as nanoparticles from the bloodstream.  At 1 hour, 
clodronate treated mice exhibit 46.7 ± 1.8 %ID (327 ± 36 %ID/g) lung uptake compared 
with 30.2 ± 3.6 %ID (204 ± 25 %ID/g) in saline treated mice.  Proportions are similar at 
the 24 hour and 48 hour time points for {Gd0.5La0.5}(
225Ac)PO4@4 GdPO4 shell@Au 
nanoparticles.  The difference in uptake between mice treated with clodronate and 
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 Figure 3.5.7 A: Nanoparticle uptake in major organs after one hour in mice injected 
with clodronate liposomes or saline followed by the {Gd0.75La0.25}(
225Ac)PO4@4 LaPO4 
shell@Au-201b system. 
 
Figure 3.5.7 B: Nanoparticle uptake in major organs after one hour in mice injected with 
clodronate liposomes or saline followed by the {Gd0.75La0.25}(
225Ac)PO4@4 LaPO4 
shell@Au-201b system.  
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Figure 3.5.7 C:  Change in lung uptake over time in mice treated with clodronate 
liposomes or saline followed by the {Gd0.75La0.25}(
225Ac)PO4@4 LaPO4 shell@Au-201b 
system. 
 
Figure 3.5.7 D: Change in lung uptake over time in mice injected with clodronate 
liposomes or saline followed by the {Gd0.5La0.5}(
225Ac)PO4@4 GdPO4 shell@Au-201b 
system. 
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those treated with saline appears to be almost exclusively due to clearance by the RES.  
Mice injected with clodronate and {Gd0.75La0.25}(
225Ac)PO4@4 LaPO4 nanoparticles show 
7.1% higher uptake in the lung than their saline-injected counterparts.  Combined 
increases in liver and spleen uptake by the saline-injected mice (7.3%) mirror the 
decrease in lung uptake.  The drastic difference in lung uptake after a time as short as 1 
hour indicates how quickly the RES clears the nanoparticles from circulation without 
pre-injection of clodronate liposomes.  Unlike many antibodies, mAb 201b quickly 
localizes to its target tissue due to the vascular availability of the thrombomodulin 
receptor.  This short targeting time allows high uptake even with RES interference.  After 
knocking out the RES, nanoparticle uptake and residence time in lung approaches that 
of the unconjugated antibody.   
 In addition to increasing lung uptake, clodronate liposomes also prolong 
residence time in lung tissue.  After 24 hours, only 35% of the activity from 
{Gd0.75La0.25}(
225Ac)PO4@4 LaPO4@Au nanoparticles clears from the lung in the 
clodronate treated mice compared with 81.3% in the saline treated mice over the same 
time period.  {Gd0.5La0.5}(
225Ac)PO4@4 GdPO4 shell@Au nanoparticles also show 
prolonged nanoparticle residence time in lung tissue.  After 24 hours, 21.6% of the initial 
uptake in the lung clears in the clodronate treated mice while 33.1% of the initial 
activity clears in the non-clodronate treated mice.   
 The nanoparticle-mAb 201b conjugates show high retention of 213Bi in the target 
lung tissue.  After 1 hour, 70.4 ± 0.8% of the 213Bi remains in the lung.  This number 
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increases to 91.4 ± 0.7% after 24 hours.  Electron microscopy of non-radioactive 
{Gd0.5La0.5}(
225Ac)PO4@4 GdPO4 shell@Au-mAb 201b conjugates shows the conjugates 
both lining the vascular space connected to lung epithelium, and internalized into the 
lung epithelial cells.  Figure 3.5.4 further shows NPs during the process of endocytosis 
into a lung epithelial cell.  Retention of daughter radionuclides by the nanoparticles 
themselves should theoretically remain constant and can be measured as previously 
described.48  As the nanoparticles are internalized in vivo, the cell itself augments the 
inherent capability of the nanoparticles to contain daughter radionuclides, increasing 
the effective daughter sequestration at the target site.   
 Therapy experiments using the EMT-6 model system show multiple small lung 
colonies.  Group 1 (PBS) averaged 77.6 ± 34.5 colonies per tissue section area.  Group 2 
(nanoparticles with competition) showed fewer colonies (57 ± 22.3 colonies per slide).  
Finally, group 3 (targeted nanoparticles without competition) had drastically fewer 
colonies with only 20.8 ± 7.5 colonies per slide.  Images of a representative section of 
tissue from each treatment group are shown in Figure 3.7.6.  Additionally, Figure 3.7.7 
shows a magnified version of the PBS treatment group with labels for tumor colonies 
and artifactual staining of macrophages/type II alveolar cells. 
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Figure 3.5.8: Stained slides showing EMT-6 tumor colonies present in lung tissue of mice 
treated with PBS, {Gd0.5La0.5}(
225Ac)PO4@GdPO4@Au nanoparticles with competition 
from mAb 201b, or those same particles without competition. 
 
Figure 3.5.9:  A stained slide from the PBS treatment group labeling lung tumor colonies 
as well as artifactual staining of macrophages and type II alveolar cells. 
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 The EMT-6 therapy experiment shows promising results for future work with 
more specific antibody targeting.  Despite targeting the organ rather than the tumor 
cells, the treatment group shows clear, statistically significant (p = 0.019) decreases in 
tumor colony growth relative to both PBS and competition from free antibody (p = 
0.020).  Competition with non-radioactive mAb 201b decreases lung uptake by more 
than a factor of 17.  However, the lung in the competition group still receives ~1.0 kBq 
of 225Ac after one hour.  This small amount of 225Ac is insufficient to produce a significant 
(p = 0.300) therapeutic effect relative to PBS controls.  Higher uptake in the lung in the 
treatment group (17.3 kBq after one hour) produces the larger therapeutic effect.  No 
abnormal side effects were observed during the 1 week observation period.  TEM 
images from the mice confirm no inflammation in tissues of the kidney as a result of 
radiation or nanoparticle exposure.  Previous experiments with 225Ac and EMT-6 tumors 
led to pulmonary fibrosis and renal failure from failure to retain 213Bi daughters in the 
target tissue.107  Future therapeutic doses could therefore likely be increased without 
inducing fatal side effects.  
3.5.3 Brain Targeting with Anti-Synaptophysin and Anti-GFAP 
 Utilizing targeted, short range therapeutics based on α particles could 
revolutionize treatment of tumors in vital organs such as the brain.  Due to the vital 
importance of the brain in regulating bodily function, a number of evolutionary 
protections have developed to limit the flow of non-essential material into the tissue.  
While the series of tight junctions and barrier cells that constitute the blood-brain 
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barrier protect brain tissue from pathogens, they also frustrate attempts to deliver 
therapeutics to the brain.  Difficulty associated with side effects of neurosurgery often 
precludes surgical resection of brain tumors depending on the location of the neoplasm.  
Nanoparticles of approximately 20 nm metallic diameter or smaller show the ability to 
traverse the blood-brain barrier, sparking interest in nanoparticle-based therapies for 
central nervous system (CNS) disorders such as Alzheimer’s disease.108,109   
 In vitro, nanoparticles bound to antibodies relevant to CNS tissue retain their 
biological activity.  Murine brain tissue sections incubated with anti-synaptophysin 
labeled {Gd0.5La0.5}PO4@4 GdPO4 shell@Au nanoparticles show binding to the basal 
ganglia and synapses.  Surrounding white matter does not show staining, indicating that 
the antibody retains its biological activity and specificity after binding to the 
nanoparticle.  The staining process involves a number of steps.  First, the nanoparticle-
primary antibody conjugates bind their antigen receptors in the brain.  Next, a 
secondary antibody contains a peroxidase enzyme and binds to the primary antibody in 
the tissue section.   In peroxide, DAB is converted into a brown, insoluble product and 
gives a brown stain.  Figure 3.5.10 shows the immunohistochemistry of anti-
synaptophysin labeled nanoparticles. 
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Figure 3.5.10:  Immunohistochemistry of brain tissue with anti-synaptophysin labeled 
nanoparticles.  Anti-synaptophysin labeled nanoparticles maintain biological activity and 
specificity after binding to the nanoparticles.  Basal ganglia cells with nanoparticles 
bound are stained by the DAB color agent while adjacent white matter is not. 
 Similarly, anti-GFAP labeled nanoparticles retain their affinity and specificity for 
receptors after binding to the nanoparticle surface.  Figure 3.5.11 shows 
immunohistochemistry in normal murine brain.  Astrocyte cells show staining by the 
DAB color agent, while surrounding brain tissue does not.  Blood vessels in the brain 
exhibit artifactual staining as well.   
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Figure 3.5.11:  Immunohistochemistry of brain tissue with anti-GFAP labeled 
nanoparticles.  Anti-GFAP labeled nanoparticles also retain their affinity and specificity 
for biological targets after binding to the nanoparticle surface.  Brown areas indicated 
by large arrows illustrate astrocytes while small arrows illustrate artifactual staining of 
blood vessels. 
 For in vivo brain receptor experiments, mice were cannulated in the left femoral 
or axillary vein via partial surgical dissection.  The surgical area was first shaved, then 
dissected using auto-cauterizers to minimize blood loss.  This technique ensures that all 
of the injected dose reaches the bloodstream for consistent, reliable delivery.  Utilizing a 
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catheter also allows for multiple injections using a single point.  Figure 3.5.12 shows the 
catheter inserted into a mouse femoral vein. 
 
Figure 3.5.12:  A catheter inserted into the left femoral vein aids injection 
reproducibility and allows for multiple injections at a single site. 
 Biodistribution experiments performed with NAA indicate that nanoparticle-mAb 
conjugates exhibit uptake in the brain.  Both anti-synaptophysin and anti-GFAP 
antibodies show uptake of 0.1 % ID.  In each case, the measurement strained MURR’s 
detection limit of NAA for gold of 0.1 ng.  However, the low level of detection is 
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consistent across six mice, lending credibility to the measurement.  Unlabeled 
nanoparticles were not detected in the brain tissue in any of the mice examined. 
 In order to confirm that the nanoparticle-mAb conjugates are specifically 
targeting their receptors in the brain and not merely present in the blood vasculature, 
brain tissue sections were fixed and examined by TEM.  Figures 3.5.13 and 3.5.14 show 
representative images of anti-synaptophysin labeled nanoparticles present at CNS 
synapses and anti-GFAP labeled nanoparticles present by astrocytes.   
 Mannitol creates a hyperosmotic environment in CNS arteries, causing water loss 
in the CNS epithelial cells and stretching the tight junctions.110  TEM images show that 
the tight junctions of the blood brain barrier have not been disrupted, despite injection 
of mannitol for that purpose.  Because the tight junctions remain largely intact, another 
mechanism must be responsible for the presence of large nanoparticles in the brain.  As 
in the lung, the nanoparticles most likely extravasate out of the vasculature through an 
endocytotic mechanism.  Vascular receptors similar to synaptophysin and GFAP mediate 
the endocytosis, importing only those materials necessary to CNS function.  
Nanoparticles bound to the anti-synaptophysin and anti-GFAP antibodies piggyback on 
this interaction, and are also endocytosed. 
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Figure 3.5.13: {Gd0.5La0.5}PO4@4 GdPO4 shell@Au nanoparticles labeled with anti-
synaptophysin bind receptors in CNS synapses. 
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Figure 3.5.14: {Gd0.5La0.5}PO4@4 GdPO4 shell@Au nanoparticles labeled with anti-GFAP 
bind receptors in astrocytes. 
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3.6 Summary of Findings 
 A central problem facing in vivo α generators has been control of daughter 
radionuclides.  Historically, this lack of retention has led to lethal dose to non-target 
organs, limiting the efficacy of these systems.  The work presented in Chapter 3 
elucidates a general solution to the problem of daughter retention through the use of 
layered nanoparticles.  The most successful system consisting of {Gd0.5La0.5}PO4@4 
GdPO4 shell@Au nanoparticles contained 90% of the first decay daughter, 
221Fr, in vitro.  
In vivo results show retentions of > 90% of the third decay daughter, 213Bi, after 24 
hours.  Retention in vivo increases over time as a result of higher percentages of 
endocytosed nanoparticles.  Finally, the nanoparticles can be linked to a variety of 
different targeting agents for treatment of a wide variety of neoplastic disease. 
 Given the success of the layered nanoparticle system in containing daughter 
emissions from 225Ac, the general strategy should be extended to other α-generator 
radionuclides such as 227Th or 223Ra.  Diversifying to these other α-emitters would allow 
clinical tailoring of α energies and daughter chemistry/half-lives to the specific disease.  
Preparing a variety of layered nanoparticle formulations which work with α-generator 
radionuclides will decrease the time required for clinical translation once these 
radionuclides become available in large quantities. 
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Chapter 4: 
FUTURE DIRECTIONS AND ONGOING WORK 
 
 
4.1 Other Lanthanides as Radiotherapeutics 
4.1.1 Nuclear and Chemical Properties of the Lanthanides 
 While the nanoparticles examined in this work focused on utilizing lanthanum 
and gadolinium, a number of other lanthanides should co-crystallize into LnPO4 
nanoparticles.  Fortunately, a number of other lanthanides also possess favorable 
nuclear properties for β- radiotherapy.  A similar synthetic process and gold surface 
modification should work for a variety of different lanthanides.  Moving across the 
period, the lanthanide contraction causes large disparities in ionic radii.  Extremes such 
as La3+ (1.18 Å) and Lu3+ (1.00 Å) may not co-crystallize.97  However, mixed lanthanide 
particles may not be necessary if the lanthanide possesses a sufficient magnetic 
moment to be separated magnetically. 
 Many lanthanides are under consideration or currently in use for biomedical 
purposes including 149Pm (β- cancer therapy),111 153Sm (Quadramet, β- pain palliation in 
bone metastases),112Eu (fluorescence imaging probes),113 159Gd (Auger electron cancer 
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therapy),114 161Tb (β- cancer therapy),115 166Dy/166Ho (β- arthritis therapy)116, 169Er (β- 
arthritis therapy),117 175Yb (β- bone pain palliation),118 and 177Lu (β- cancer therapy).119  
Only a few of these (149Pm, 166Ho, and 177Lu) are available as no carrier added 
radionuclides.  For all of the other radionuclides, only a small percentage of 
bioconjugates will deliver radiation to the intended target.  Incorporating the 
radionuclides into a nanoparticle would dramatically increase the amount of 
radioactivity bound to each targeting vector.  Radionuclides that are available no carrier 
added could also use nanoparticle constructs to increase the delivered dose.  In order to 
determine the feasibility of this approach, nanoparticles composed of TbPO4, HoPO4, 
and LuPO4 were synthesized.   
4.1.2  Synthesis and Characterization of TbPO4, HoPO4, and LuPO4 Nanoparticles 
 Nanoparticles consisting of TbPO4, HoPO4, and LuPO4 were synthesized similarly 
to 3.2.3.  Briefly, 1 mL of 0.1 M Tb(NO3)3∙5 H2O, HoCl3, or LuCl3∙6 H2O was added to a 5 
mL v-bottom vial with spin vane and 2 mL of 0.1 M Na-TPP.  Each vial was heated for 3 
hours at 90oC.  Nanoparticles were transferred into scintillation vials and placed by a 0.6 
T surface field NdFeB magnet to determine if they could be magnetically separated.  
LuPO4 nanoparticles were dialyzed against 18 MΩ water using a 10 kDa MWCO 
regenerated cellulose membrane overnight, then collected and dried over low heat.  
Dried particles were crushed using a mortar and pestle, then examined using XRD as 
described in 3.2.9. 
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4.1.3  Results and Discussion 
 TbPO4, HoPO4, and LuPO4 all formed nanoparticle solutions similar to previous 
LnPO4 combinations.  TbPO4 and HoPO4 nanoparticles both showed strong preference 
towards the magnet and separated cleanly.  LuPO4 nanoparticles on the other hand 
showed no preference for the magnet and settled uniformly on the bottom of the vial.  
Of the lanthanides, gadolinium is most often used as a magnetic agent, due to its 7 
unpaired f electrons in its preferred 3+ oxidation state.  While terbium (6 unpaired 
electrons in the 3+ oxidation state) and holmium (4 unpaired electrons in the 3+ 
oxidation state) should exhibit a lower paramagnetic magnetic moment than 
gadolinium, it still appears sufficient to facilitate magnetic separation.  In contrast, 
lutetium (0 unpaired electrons in the 3+ oxidation state) shows no paramagnetic 
moment.  As a result, 177Lu would need to be paired with a more magnetic lanthanide 
such as gadolinium in order to separate the nanoparticles magnetically. 
 XRD studies indicate that LuPO4 crystallizes in the anhydrous monazite crystal 
phase, similar to that observed for GdPO4 and mixtures of LaPO4 and GdPO4.  The XRD 
pattern is shown below in Figure 4.1.1.  Rietvield refinement indicates that the grain size 
of these particles is 1.76 nm, somewhat smaller than the other LnPO4 systems 
previously analyzed.   
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Figure 4.1.1: XRD pattern of LuPO4 indicates a monazite crystal structure with grain size 
of 1.76 nm. 
4.1.4 Conclusions 
 A number of lanthanides could easily work in the platform described in Chapter 
3.  Given the large quantity of 177Lu produced at MURR, investigation of this radionuclide 
makes particular sense at Missouri.  XRD studies indicate that a nanoparticle similar in 
structure to previously studied constructs is formed under similar conditions.  Ongoing 
experiments involving synthesis of a mixed {Gd0.5
177Lu0.5}PO4 nanoparticle are in 
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progress under the direction of fellow graduate student Nick Sobol.  Gold coating of the 
particles should occur analogously and similarly facilitate attachment of biologically 
relevant targeting agents. 
 
4.2 Potential for 227Th or 223Ra generators 
4.2.1 Impetus for 227Th or 223Ra generators 
 As mentioned in Chapter 1, 227Th and 223Ra are also being considered as potential 
in vivo α generator radionuclides.  Further, the higher availability of 227Th and 223Ra 
avoid the research and clinical trial bottleneck found with 225Ac.  While 223Ra as 
Alpharadin inherently targets bone metastases, incorporation into a LnPO4 nanoparticle 
could broaden its clinical applicability.  In order to test the ability of LnPO4 as a carrier 
for 223Ra, barium was added to a synthesis of {Gd0.5La0.5}PO4 nanoparticles as a 
surrogate for radium.  Radium and barium share a common preferred oxidation state 
(2+) and similar 8-coordinate ionic radii (Ba = 1.56 Å, Ra = 1.62 Å).97 
 Similarly, 227Th should be investigated for its potential to dope into LnPO4 
nanoparticles.  Previous work indicates that the lanthanide Ce+4 cocrystallizes well with 
La+3 to form fluorescent rhabdophane nanocrystals.120  The Ce+4 ion should function well 
as a surrogate for 227Th.  Both elements easily access the 4+ oxidation state and have 
similar 8-coordinate ionic radii (Ce4+ = 1.11 Å, Th4+ = 1.19 Å).97   
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4.2.2 Barium nanoparticles experimental 
 A solution of 500 μL of 0.1 M LaCl3∙7 H2O, 500 μL of 0.1 M GdCl3∙6 H2O, 50 μL of 
0.1 M BaCl2, and 2 mL of 0.1 M Na-TPP were mixed in a 5 mL v-bottom vial with spin 
vane.  The solution was heated for 3 hours at 90oC.   
4.2.3 Ba nanoparticles results and discussion 
 Nanoparticles with Ba dopants formed large aggregates that would not disperse 
in solution.  It is likely that Ba3(PO4)2 clumps formed rather than doping into the LnPO4 
nanoparticles.  The oxidation state and size mismatch between barium and the 
lanthanides likely preclude co-crystallization.  While it may be possible to dope 223Ra 
into LnPO4 nanoparticles on the tracer level, other barium containing nanoparticles such 
as BaTiO3,
121 BaSO4,
122 or BaFe12O19
123 should be more promising. 
4.2.4 Conclusion 
 Oxidation state and size appear to be the defining factors that influence co-
crystallization.  While 223Ra may not work well with LnPO4, 
227Th could likely co-
crystallize into LnPO4 nanoparticles containing a significant fraction of Ce
4+ ions.  
Successful doping of Ce4+ ions into LnPO4 nanoparticles has already been 
demonstrated.124 Additionally, thorium doping itself could be done with natural thorium 
rather than the less common 227Th in initial experiments. 
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4.3 Future Clinical Applications 
 While proof of principle targeting with mAb 201b showed high, receptor specific 
uptake, the thrombomodulin target has little clinical relevance to cancer therapy.  
Additional antibodies which target receptors overexpressed on tumors should be 
utilized to determine clinical applicability of the nanoparticle system.  As detailed in 
Sections 1.3 and 1.4, the short range of α emission and large size of nanoparticles limit 
potential application of the nanoparticle system to small metastases with vascular 
targets, circulating neoplasms, peritoneal tumors, and intratumoral injections.  Utilizing 
vascular targeting agents such as F340 removes the necessity for nanoparticles to 
extravasate out of the vasculature.   
 Another potentially viable strategy to capitalize on the advantages of 
nanoparticle systems involves targeting cancers of the circulatory system.  In particular, 
a wide variety of leukemias and lymphomas should be treatable with appropriate 
targeting agents.  Targets such as CD20 (the same target used in the clinically approved 
BEXXAR radiopharmaceutical)125 and CD45126 are overexpressed on a number of blood-
borne cancers.  Antibodies that target these receptors, such as 1F5127 (CD20) and BC8128 
(CD45), are currently being investigated in cell pellet and mouse studies with the 
described LnPO4 nanoparticle system in collaboration with the Fred Hutchinson Cancer 
Research Center in Seattle, Washington. 
127 
 
 Additionally, tumors of the peritoneum tend to form thin films.129  Cancers 
originating in the peritoneal cavity (ovarian, liver, pancreatic, colorectal, gastric, and 
peritoneal mesothelioma) have high rates of locoregional metastasis to other locations 
within the peritoneal cavity.130  Administration of nanoparticles directly into the 
peritoneal cavity would also bypass the need for extravasation out of the vasculature.  
Additionally, α therapy is ideal for treating the thin cancerous films and metastases 
found in peritoneal cancers.  Panitumumab, an antibody against EGFR conjugated to the 
particles in 3.4, may be an effective therapy for these peritoneal cancers.  
Biodistribution studies are currently underway in collaboration with the National Cancer 
Institute. 
 Finally, α therapeutic nanoparticles can be injected directly into tumors as a 
brachytherapy analog.  The solution of nanoparticles may perfuse throughout the target 
tissue, providing better coverage and lower whole body dose than current seed based 
therapies.  More work is needed to determine the degree of perfusion in these 
therapies as well as the tissue retention of the nanoparticles over time. 
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APPENDIX 
 
 
 
Appendix 1: Total biodistribution of starch-bombesin gold nanoparticles 
Compound: 198Au-NP (Starch)  (I.P.) 130 kBq/100μL 
Date: 8/18/2010 Tumor: PC-3   
Time : 2 Hour Strain: SCIDs 5 mice 
Blocker:  Saline (I.V.) Dose Cts. 503838   
Organ Avg %ID STDEV Avg%ID/g STDEV 
Blood 9.83 5.27 7.26 3.20 
Heart 0.06 0.06 0.37 0.46 
Lung 0.12 0.07 0.46 0.41 
Liver 5.34 2.33 4.55 2.21 
Spleen  0.85 0.36 9.32 5.72 
Stomach 3.87 1.26 13.17 11.59 
L Int 5.72 2.88 5.82 3.36 
Sm Int 12.93 9.61 10.64 8.63 
Kidney 0.42 0.33 1.28 1.21 
Urine  0.01 0.01     
Abdominal Fat 31.86 28.55 127.26 115.98 
Muscle 0.01 0.01 0.03 0.03 
Bone 0.00 0.00 0.05 0.05 
Bladder 0.23 0.14 7.81 6.84 
Brain 0.00 0.00 0.00 0.00 
Pancreas 0.39 0.43 11.05 10.22 
Carcass 35.39 19.32 13.67 1.05 
Tumor A 0.02 0.02 0.06 0.06 
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Compound: 198Au-NP (Starch)  (I.P.) 130 kBq/100μL 
Date: 8/18/2010 Tumor: PC-3   
Time : 2 Hour Strain: SCIDs 5 mice 
Blocker:  Cold BBN (I.V.)  Dose Cts. 503838.2 
Organ Avg %ID STDEV Avg%ID/g STDEV 
Blood 12.81 10.87 9.44 6.95 
Heart 0.07 0.11 0.61 0.97 
Lung 0.58 0.33 2.57 1.71 
Liver 7.70 2.06 6.62 1.48 
Spleen  0.78 0.45 8.43 7.22 
Stomach 6.48 3.20 9.23 4.26 
L Int 5.35 1.13 5.49 1.22 
Sm Int 10.11 7.29 6.67 3.72 
Kidney 0.84 0.38 2.59 1.15 
Urine  0.01 0.01     
Abdominal Fat 20.19 16.23 89.28 96.06 
Muscle 0.12 0.22 0.70 1.43 
Bone 0.01 0.01 0.18 0.36 
Bladder 0.23 0.13 6.75 5.80 
Brain 0.00 0.00 0.01 0.01 
Pancreas 0.92 0.31 22.01 9.07 
Carcass 42.13 6.84 11.04 0.44 
Tumor A 0.05 0.04 0.17 0.13 
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Compound: 198Au-BBN-NP  (I.P.)  130 kBq/100μL 
Date: 8/18/2010 Tumor: PC-3  
Time : 2 Hour Strain: SCIDs 5 mice 
Blocker:  Saline (I.V.)  Dose Cts. 541810.2  
Organ Avg %ID STDEV Avg%ID/g STDEV 
Blood 7.10 18.18 3.66 5.36 
Heart 0.05 0.08 0.34 0.65 
Lung 0.08 0.12 0.33 0.52 
Liver 3.71 3.67 2.23 2.78 
Spleen  0.43 0.51 6.52 6.98 
Stomach 3.07 2.19 4.22 3.34 
L Int 2.06 2.13 2.22 2.69 
Sm Int 2.79 3.38 1.80 2.36 
Kidney 0.22 0.41 0.67 1.08 
Urine  3.59 6.42     
Abdominal Fat 42.62 40.30 136.53 135.59 
Muscle 0.01 0.03 0.02 0.02 
Bone 0.00 0.00 0.05 0.08 
Bladder 0.21 0.39 7.74 12.10 
Brain 0.00 0.00 0.00 0.00 
Pancreas 0.36 2.16 7.79 9.06 
Carcass 39.80 30.12 21.84 2.09 
Tumor A 0.01 0.01 0.04 0.07 
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Compound: 198Au-BBN-NP  (I.P.)  130 kBq/100μL 
Date: 8/18/2010 Tumor: PC-3   
Time : 2 Hour Strain: SCIDs 5 mice 
Blocker:  Cold BBN (I.V.)  Dose Cts. 541810.2 
Organ Avg %ID STDEV Avg%ID/g STDEV 
Blood 10.66 10.27 7.95 6.31 
Heart 0.02 0.02 0.08 0.20 
Lung 0.27 0.31 1.04 1.62 
Liver 3.50 3.49 3.19 2.89 
Spleen  0.75 0.78 8.06 12.04 
Stomach 2.26 2.50 4.45 6.23 
L Int 3.46 3.65 4.06 4.73 
Sm Int 5.06 5.12 3.78 3.28 
Kidney 0.65 0.91 1.76 3.00 
Urine  0.17 0.34     
Abdominal Fat 18.01 22.95 79.45 143.92 
Muscle 0.02 0.02 0.08 0.10 
Bone 0.00 0.00 0.06 0.07 
Bladder 0.09 0.08 1.78 3.13 
Brain 0.00 0.00 0.00 0.00 
Pancreas 0.56 0.56 9.87 16.93 
Carcass 61.58 34.05 9.99 1.69 
Tumor A 0.01 0.01 0.02 0.03 
 
 
 
 
 
 
132 
 
Appendix 2: XRD scan parameters 
Goniometer=PW3050/60 (Theta/Theta); Minimum step size 2Theta:0.001; Minimum 
step size Omega:0.001 
 Sample stage=Multi purpose sample stage; Minimum step size Phi:2.5 
      Diffractometer system=XPERT-PRO 
 Measurement program=10-60 90 min, Owner=CNMSuser, Creation date=6/30/2011 
1:41:07 PM 
Scan Axis Gonio 
Start Position [°2Th.] 16.0682 
End Position [°2Th.] 59.9802 
Step Size [°2Th.] 0.0080 
Scan Step Time [s] 59.6900 
Scan Type Continuous 
PSD Mode Scanning 
PSD Length [°2Th.] 2.12 
Offset [°2Th.] 0.0000 
Divergence Slit Type Fixed 
Divergence Slit Size [°] 0.2500 
Specimen Length [mm] 10.00 
Measurement Temperature [°C] 25.00 
Anode Material Cu 
K-Alpha1 [Å] 1.54060 
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K-Alpha2 [Å] 1.54443 
K-Beta [Å] 1.39225 
K-A2 / K-A1 Ratio 0.50000 
Generator Settings 40 mA, 45 kV 
Diffractometer Type 0000000011010092 
Diffractometer Number 0 
Goniometer Radius [mm] 240.00 
Dist. Focus-Diverg. Slit [mm] 100.00 
Incident Beam Monochromator No 
Spinning No 
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Appendix 3: Antibody:Nanoparticle Ratio Calculation 
Nanoparticle mass: 
Mass of individual NP = core volume (core density) + (layer volume) (layer density) 
 = 4/3π (1.12*10^-6 cm)^3 (5 g/cm^3) + (4/3π (1.17*10^-6 cm)^3 - 4/3π 
 (1.12*10^-6 cm)^3) (19.3 g/cm^3) 
 = 4.89*10^-18 g/nanoparticle 
Number of nanoparticles: 
Number of nanoparticles = mass of nanoparticles/mass of individual nanoparticle 
Mass of nanoparticles determined by synthetic conditions 
 = 0.00088 g /4.89*10^-18 g  
 = 1.8*10^14 nanoparticles 
Antibody mass determined by Lowry assay or 125I radiolabeling 
Panitumumab antibodies = mass mAb/molecular weight mAb * Avogadro’s number 
 = 0.00019 g/150,000 g/mol *6.022*10^23 molecules/mol 
 =7.63*10^14 antibodies 
Ratio of panitumumab:nanoparticle: 
 7.63*10^14 antibodies/1.8*10^14 nanoparticles = 4.2 antibodies/nanoparticle 
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